

# A genetically informed Registered Report on adverse childhood experiences and mental health

Received: 24 April 2020

Accepted: 13 October 2022

Published online: 08 December 2022

 Check for updates

Jessie R. Baldwin<sup>1,2</sup>✉, Hannah M. Sallis<sup>3,4,5,6</sup>, Tabea Schoeler<sup>1</sup>, Mark J. Taylor<sup>7</sup>, Alex S. F. Kwong<sup>3,8</sup>, Jorim J. Tielbeek<sup>9</sup>, Wikus Barkhuizen<sup>1</sup>, Varun Warriar<sup>10</sup>, Laura D. Howe<sup>3</sup>, Andrea Danese<sup>2,11,12</sup>, Eamon McCrory<sup>1,13</sup>, Fruhling Rijdsdijk<sup>14</sup>, Henrik Larsson<sup>7,15</sup>, Sebastian Lundström<sup>16,17</sup>, Robert Karlsson<sup>7</sup>, Paul Lichtenstein<sup>7</sup>, Marcus Munafò<sup>3,4,5</sup> & Jean-Baptiste Pingault<sup>1,2</sup>

Children who experience adversities have an elevated risk of mental health problems. However, the extent to which adverse childhood experiences (ACEs) cause mental health problems remains unclear, as previous associations may partly reflect genetic confounding. In this Registered Report, we used DNA from 11,407 children from the United Kingdom and the United States to investigate gene–environment correlations and genetic confounding of the associations between ACEs and mental health. Regarding gene–environment correlations, children with higher polygenic scores for mental health problems had a small increase in odds of ACEs. Regarding genetic confounding, elevated risk of mental health problems in children exposed to ACEs was at least partially due to pre-existing genetic risk. However, some ACEs (such as childhood maltreatment and parental mental illness) remained associated with mental health problems independent of genetic confounding. These findings suggest that interventions addressing heritable psychiatric vulnerabilities in children exposed to ACEs may help reduce their risk of mental health problems.

Adverse childhood experiences (ACEs) are well-established risk factors for mental health problems. For example, a wealth of research has shown that children exposed to abuse, neglect and dysfunctional home environments (such as domestic violence, parental separation, parental mental illness, criminal behaviour or parental substance abuse) have a higher risk of developing internalizing disorders such as depression and anxiety<sup>1–4</sup>, and externalizing disorders such as conduct disorder and attention-deficit hyperactivity disorder (ADHD)<sup>5–7</sup>. However, as highlighted recently by policymakers<sup>8</sup>, charities<sup>9</sup> and scientists<sup>10,11</sup>, the extent to which ACEs cause mental health problems is not known. This is because ACEs are not randomly distributed in the population, and

children exposed to ACEs are likely to have other risk factors for mental health problems. In addition to wider environmental risks, one key potential vulnerability is genetic liability to mental health problems<sup>12</sup>.

There are at least two reasons why children exposed to ACEs might have an elevated genetic liability to mental health problems. First, parents with mental health problems may pass on genetic variants conferring psychopathology risk to their children and may provide them with an adverse rearing environment. This represents a passive gene–environment correlation<sup>13,14</sup> and is plausible as parental mental illness is considered to be an ACE, and other ACEs often occur in families in which parents have mental health difficulties<sup>15</sup>. Second, a child with

early phenotypic expressions of genetic liability to mental health problems might be more likely to elicit harsh parenting or stress responses in their parents (for example, depressive symptoms). This represents an evocative gene–environment correlation<sup>13,14</sup> and has been evidenced in adoption studies, whereby children at genetic risk of externalizing problems were more likely to experience negative parenting from adoptive parents<sup>16,17</sup>. Importantly, if children with increased genetic liability to mental health problems have an elevated risk of ACEs, the association between ACEs and mental health problems may partly reflect genetic confounding.

It is important to investigate the extent to which genetic influences contribute to associations between ACEs and mental health to provide insights into causality and interventions. For example, if the associations are partly confounded by genetic influences, then the causal contribution of ACEs to mental health is likely to be smaller than estimates from non-genetically informative studies. If this is the case, then even if we succeeded in implementing effective primary prevention of ACEs, this would only partly reduce children's risk of mental health problems. In addition, secondary preventative strategies that support exposed children and address heritable vulnerabilities to psychopathology would be needed to reduce their risk of developing mental health problems. For example, this could include skill-building components to manage negative emotions and behaviours as part of trauma-focused cognitive behavioural therapy<sup>9</sup>. Of course, there is a moral imperative to reduce the likelihood that children will experience ACEs, regardless of the degree to which they impact mental health. However, this research can improve our mechanistic understanding of the relationship between ACEs and mental health in ways that can help optimize approaches to prevention and intervention.

To examine the extent to which genetic influences contribute to associations between ACEs and mental health, particular genetically informed methods are needed. Twin methods (which have traditionally been used to test for genetic confounding)<sup>18,19</sup> can be limited because many ACEs affect all children in a family, and thus, twins typically do not differ in their exposure. In addition, the adoption design (which can rule out genetic confounding due to passive gene–environment correlation) has limited utility because ACEs are rare in adoptive families<sup>20</sup>. Fortunately, recent advances in genome-wide association studies (GWASs) have allowed us to assess genetic influences in samples of unrelated individuals through polygenic scores. Polygenic scores capture common genetic influences by summing the effects of many genetic variants (known as single nucleotide polymorphisms (SNPs)) on a trait into a single individual-level score. Through using polygenic scores, we can test whether (1) children with increased genetic liability to mental health problems are more likely to be exposed to ACEs (that is, gene–environment correlation) and (2) such genetic influences contribute to the associations between ACEs and mental health (that is, genetic confounding).

To examine gene–environment correlation, we can test whether a child's polygenic score for a mental health problem (for example, depression) predicts their exposure to ACEs. Three prospective studies employing this method have suggested that children with genetic liability to mental health problems may be more likely to experience ACEs. First, Sallis and colleagues<sup>21</sup> found that children with higher polygenic scores for schizophrenia, ADHD, bipolar disorder, depression and neuroticism had a greater risk of exposure to broadly defined childhood trauma (including maltreatment, bullying and domestic violence), with each standard-deviation increase in the polygenic score predicting childhood trauma with odds ratios ranging from 1.07 (bipolar disorder) to 1.16 (depression). Second, Zwicker and colleagues<sup>22</sup> found that young people exposed to higher levels of broadly defined childhood adversity (including maltreatment, bullying and domestic violence) had higher polygenic scores for ADHD (standardized  $\beta = 0.24$ ), but not schizophrenia. Third, Schoeler and colleagues<sup>23</sup> found that polygenic scores for depression, ADHD and risk taking (as well as body mass

index and intelligence) independently predicted exposure to bullying victimization in a multi-polygenic score model (with standardized  $\beta$ s ranging from 0.04 (risk taking) to 0.07 (depression)). These findings are also consistent with evidence from retrospective studies showing that adults reporting childhood maltreatment had higher polygenic scores for depression, schizophrenia and bipolar disorder (with odds ratios ranging from 1.03 (bipolar disorder) to 1.20 (depression))<sup>24,25</sup> as well as autism (standardized  $\beta = 0.03$ )<sup>26</sup>. However, no study has systematically tested whether polygenic scores for a range of mental health problems predict a range of different ACEs, including indicators of household dysfunction (for example, domestic violence, parental separation, parental mental illness, criminal behaviour or parental substance abuse) as well as maltreatment. It is therefore not known whether some ACEs are more strongly linked to genetic risk of mental health problems than others and whether certain genetic liabilities are particularly important in the risk of exposure to ACEs.

To examine genetic confounding, we can test the extent to which the associations between ACEs and mental health are reduced when accounting for children's polygenic scores for mental health problems<sup>27</sup>. To date, no study has examined whether this is the case for the associations between ACEs and mental health. However, studies have examined whether this is the case for related environmental experiences, such as adoption and parenting. With regard to adoption, Lehto and colleagues<sup>28</sup> found that the associations between adoption and mental-health-related outcomes in adulthood (depressive symptoms, bipolar disorder, neuroticism and life satisfaction) were attenuated by 3% (for bipolar disorder) to 18% (for life satisfaction) when controlling for the respective polygenic scores. With regard to parenting, Wertz and colleagues<sup>29</sup> found that the associations between cognitive stimulation, warm, sensitive parenting, household chaos, and a safe, tidy home environment with child educational attainment were reduced by approximately 8% when controlling for the child's polygenic score for education. Furthermore, Krapohl and colleagues<sup>30</sup> found that the associations between parental slapping or smacking with ADHD and conduct problems were attenuated by 6% and 7%, respectively, when controlling for the child's polygenic score for educational attainment.

Controlling for polygenic scores for mental health problems in this manner can indicate whether there is likely to be a genetic contribution to the association between ACEs and mental health. However, one limitation of this methodological approach is that polygenic scores capture only a small proportion of heritability and thus do not fully account for genetic confounding. This can be addressed by a newly developed genetic sensitivity analysis<sup>27</sup> that estimates shared genetic effects under scenarios in which the polygenic score captures additional genetic variance in the outcome (that is, SNP-based and/or twin-based heritability; see 'Analysis plan' in the Methods for a detailed description of this method). A recent application of this genetic sensitivity analysis found that the associations between maternal education and offspring ADHD, educational achievement and body mass index were moderately explained by shared genetic effects<sup>27</sup>, consistent with findings from children-of-twins studies and adoption designs<sup>31</sup>. For example, a latent polygenic score that captured SNP-based heritability in educational achievement (that is, 31%; ref.<sup>32</sup>) explained 50% of the association between maternal education and child educational achievement<sup>27</sup>. However, this approach has never been applied to assess the extent to which genetic influences contribute to the associations between ACEs and mental health.

In this study, we systematically investigated the role of genetic liability in the associations between ACEs and mental health problems. To do so, we used data from more than 11,000 genotyped children from two cohorts in the United Kingdom (the Avon Longitudinal Study of Parents and Children (ALSPAC)) and the United States (the Adolescent Brain Cognitive Development (ABCD) Study), with prospective measures of ACEs and mental health. (Note that the ABCD Study was not originally included in the Stage 1 pre-registration, but we used it because the original dataset, the Child and Adolescent Twin Study in

Sweden (CATSS), was not accessible after Stage 1 acceptance (detailed in the Methods.) We addressed the following aims and hypotheses (summarized in Table 1).

To examine gene–environment correlations, we investigated whether children with genetic liability to mental health problems are more likely to be exposed to ACEs (Aim 1). We addressed this by testing three hypotheses. First, we tested whether polygenic scores for mental health problems (depression, ADHD, schizophrenia and others) are associated with exposure to ACEs. We hypothesized that polygenic scores for mental health problems would be associated with an increased risk of exposure to ACEs (Hypothesis 1a). Second, we tested whether polygenic scores for certain mental health problems are more strongly associated with ACEs than other polygenic scores. We hypothesized that there would not be evidence for differential associations between polygenic scores for different mental health problems and ACEs (Hypothesis 1b), given that previous research has identified similar-sized bivariate associations between a range of polygenic scores and ACEs<sup>21</sup>. Third, we tested whether certain ACEs are linked to greater polygenic risk for mental health problems than other ACEs. We hypothesized that parental mental illness, parental substance abuse and parental criminality would be associated with higher polygenic risk for mental health problems than would maltreatment, domestic violence and parental separation (Hypothesis 1c), because the former exposures are most likely to be linked to intergenerational transmission of genetic risk for psychopathology.

To examine genetic confounding, we investigated the extent to which genetic liability to mental health problems contributes to the associations between ACEs and mental health (Aim 2). We addressed this by testing two hypotheses. First, we examined the proportions of the associations between ACEs and internalizing and externalizing problems that are explained by observed polygenic scores for mental health problems. We hypothesized that observed polygenic scores would explain a small proportion (5% to 20%) of the associations between ACEs and internalizing and externalizing problems (Hypothesis 2a), given that a similar proportion of covariation between other early environments (adoption and parental discipline) and psychopathology was captured by polygenic scores<sup>29,30</sup>. Second, we estimated the proportions of the associations between ACEs and internalizing and externalizing problems that would be explained by latent polygenic scores which capture additional heritability in mental health problems. We hypothesized that polygenic scores that capture SNP heritability in internalizing and externalizing problems would explain a moderate proportion (20% to 40%) of the associations between ACEs and these outcomes (Hypothesis 2b). This is based on evidence showing that accounting for SNP heritability in an outcome can increase the covariance captured in an association by more than double, relative to a standard polygenic score<sup>27</sup>.

## Results

### Sample description

After imputation, the samples included 6,411 participants from ALSPAC and 4,996 participants from the ABCD Study. (Note that the ABCD Study was not originally included in the Stage 1 pre-registration, but we used it because the original dataset, CATSS, was not accessible after Stage 1 acceptance. Further information on the change in sample from CATSS to the ABCD Study is reported in the Methods, ‘Change in replication cohort’.) Descriptive statistics are shown in Supplementary Table 1. Below, we report the results for the imputed samples, before testing whether the findings replicate in the complete case samples ( $N = 4,106$  in ALSPAC and  $N = 4,662$  in the ABCD Study).

### Hypothesis 1a: do children with genetic liability to mental health problems have an increased risk of ACEs?

**ALSPAC.** We first tested the associations between polygenic scores for mental health problems (depression, anxiety, bipolar disorder, autism,

ADHD, antisocial behaviour, alcohol use disorder and schizophrenia) and individual ACEs (maltreatment, domestic violence, parental mental illness, parental substance abuse, parental separation and parental criminality). To obtain a single effect size reflecting the average association between polygenic scores for mental health problems and ACEs, we pooled the results across all individual associations. On average, we found that children from ALSPAC with higher polygenic scores for mental health problems had a small increase in the odds of ACEs (pooled odds ratio (OR), 1.05; 95% confidence interval (CI), 1.01–1.10;  $P = 0.0081$ ; Fig. 1a). To examine whether this effect size was trivially small, we performed equivalence tests, which assess whether the 90% CIs for the effect size lie entirely within pre-specified equivalence bounds of  $OR = 0.94$ – $1.06$  (indexing the smallest effect size of interest; Methods, ‘Analysis plan’). The 90% CIs for the pooled association between polygenic scores for mental health problems and ACEs (1.02–1.09) did not fall completely within the equivalence bounds, suggesting that the association was of meaningful magnitude. In contrast, negative-control polygenic scores for handedness and cataracts were not associated with ACEs (pooled OR, 0.98; 95% CI, 0.94–1.02;  $P = 0.39$ ; Fig. 1b).

**ABCD.** Similar to ALSPAC, children in the ABCD cohort with greater polygenic scores for mental health problems had a small increase in odds of ACEs (pooled OR, 1.09; 95% CI, 1.03–1.15;  $P = 0.0021$ ; Fig. 2a), and the 90% CIs (1.04–1.14) did not fall completely within the equivalence bounds (0.94–1.06). Conversely, negative-control polygenic scores were not associated with ACEs (pooled OR, 1.02; 95% CI, 0.97–1.07;  $P = 0.52$ ; Fig. 2b). Taken together, the findings from both cohorts pooled across ACEs support the hypothesis that polygenic scores for mental health problems are associated with an increased risk of exposure to ACEs.

### Hypothesis 1b: are polygenic scores for certain mental health problems more strongly associated with ACEs than other polygenic scores?

**ALSPAC.** Next, we examined whether polygenic scores for mental health problems differed in their average associations with ACEs. In ALSPAC, we found that polygenic scores for various mental health problems were differentially associated with ACEs (Wald-test  $F(7, 16, 573)$ , 2.62;  $P = 0.011$ ). Pairwise comparisons showed that the polygenic scores for depression, ADHD and schizophrenia predicted average risk of ACEs more strongly than various other polygenic scores (particularly for autism and alcohol dependence; Fig. 3a). The 90% CIs for these differences did not fall entirely within the pre-specified equivalence bounds ( $-0.10$  to  $0.10$  on the log odds scale; Fig. 3a), suggesting that the differences were of a meaningful size.

**ABCD.** In the ABCD Study, polygenic scores for various mental health problems also showed different associations with ACEs (Wald-test  $F(7, 436, 521)$ , 7.68;  $P = 2.60 \times 10^{-9}$ ). Consistent with the ALSPAC findings, polygenic scores for depression, ADHD and schizophrenia showed stronger average associations with ACEs than various other polygenic scores (particularly for autism and alcohol dependence; Fig. 3b). However, in contrast to ALSPAC, polygenic scores for antisocial behaviour and bipolar disorder were more strongly associated with ACEs than some other polygenic scores (particularly autism and alcohol dependence). The 90% CIs for these differences did not fall within the equivalence bounds. The findings from both cohorts therefore do not support the hypothesis that polygenic scores for different mental health problems are equally associated with ACEs.

### Hypothesis 1c: are some ACEs linked to greater polygenic risk for mental health problems than other ACEs?

**ALSPAC.** We next examined whether the associations between polygenic scores for mental health problems and ACEs differed across ACEs.

**Table 1 | Summary of the study's research questions, hypotheses, power calculations, analyses and conditions for interpretation**

Question	Hypothesis	Sampling plan (including power analysis)	Analysis plan	Interpretations given to different outcomes
Do children with genetic liability to mental health problems have an increased risk of ACEs?	(1a) Polygenic scores for mental health problems will be associated with an increased risk of exposure to ACEs.	$N=4,700$ gives 0.96 power to detect an average odds ratio of 1.04 for the pooled association between polygenic scores and ACEs	<ul style="list-style-type: none"> <li>Use logistic regression models testing the association between each polygenic score (including negative controls) and each ACE.</li> <li>Pool the results from all logistic regression models in an aggregate meta-analysis model for associations between (1) polygenic scores for mental health problems and ACEs, and (2) negative-control polygenic scores and ACEs.</li> <li>Assess whether the 90% CI for the pooled odds ratio for the association between polygenic scores for mental health problems and ACEs lies between 0.94 and 1.06 (equivalence bounds).</li> </ul>	<ul style="list-style-type: none"> <li>A positive and statistically significant pooled association between polygenic scores for mental health problems and ACEs will suggest that children with genetic liability to psychopathology have an elevated risk of ACEs. A non-significant association will suggest the absence of evidence for this.</li> <li>If CIs for this association are within the equivalence bounds, it will suggest that children with genetic liability to psychopathology do not have a meaningful increase in risk for ACEs. If the CIs do not fall within the equivalence bounds, it will suggest that the association is of meaningful magnitude.</li> <li>If the pooled association between negative-control polygenic scores and ACEs is statistically significant, it will suggest that the results may be affected by biases in polygenic scores. If this association is non-significant, it will suggest that such biases do not affect the results.</li> <li>Hypothesis 1a will be supported if (1) the pooled association between polygenic scores for mental health problems and ACEs is statistically significant, (2) the CIs for this association do not fall within the equivalence bounds, and (3) the pooled association between negative-control polygenic scores and ACEs is non-significant.</li> </ul>
Are polygenic scores for certain mental health problems more strongly associated with ACEs than other polygenic scores?	(1b) Polygenic scores for different mental health problems equally predict exposure to ACEs.	$N=4,700$ gives 1.00 power to detect a significant difference of 0.11 in odds ratios reflecting the average association between different polygenic scores and ACEs, using a Wald test.	<ul style="list-style-type: none"> <li>Use a structural equation model to estimate the associations between each polygenic score and each ACE (Supplementary Fig. 1). Calculate the average association between each polygenic score and all ACEs.</li> <li>Conduct a Wald test to assess whether the average association of each polygenic score with ACEs varies across polygenic scores.</li> <li>If the Wald test is significant, conduct pairwise comparisons to assess which polygenic scores differ in prediction of ACEs.</li> <li>Calculate differences in log odds ratios between average associations between different polygenic scores and ACEs, and assess whether the 90% CIs for the differences fall within <math>-0.10</math> to <math>0.10</math> (equivalence bounds).</li> </ul>	<ul style="list-style-type: none"> <li>A statistically significant Wald test will suggest that polygenic scores differ in their association with ACEs. Follow-up pairwise comparisons will show which polygenic scores differ. A non-significant Wald test would suggest the absence of evidence for differences between polygenic scores in association with ACEs.</li> <li>If the CIs for differences between polygenic scores in their associations with ACEs are within the equivalence bounds, it will suggest that there are not meaningful differences between polygenic scores in their association with ACEs. If the CIs do not fall within the equivalence bounds, it will suggest that the differences are of meaningful magnitude.</li> <li>Hypothesis 1b will be supported if (1) the Wald test is non-significant and (2) CIs for differences between polygenic scores are within the equivalence bounds.</li> </ul>
Are some ACEs linked to greater polygenic risk for mental health problems than other ACEs?	(1c) Parental mental illness, parental substance abuse and parental criminality will be associated with higher polygenic risk for mental health problems than will maltreatment, domestic violence and parental separation.	$N=4,700$ gives 1.00 power to detect a significant difference of 0.10 in odds ratios reflecting the average association between polygenic scores and different ACEs, using a Wald test.	<ul style="list-style-type: none"> <li>Use a structural equation model to estimate the associations between each polygenic score and each ACE (Supplementary Fig. 1).</li> <li>Calculate the average association between each ACE and all polygenic scores.</li> <li>Conduct a Wald test to assess whether the average effect of all polygenic scores on each ACE varies across ACEs.</li> <li>If the Wald test is significant, conduct pairwise comparisons to assess which ACEs differ in the association with polygenic scores.</li> <li>Calculate differences in log odds ratios between average associations between different ACEs and polygenic scores, and assess whether the 90% CIs for the differences fall within <math>-0.05</math> to <math>0.05</math> (equivalence bounds).</li> </ul>	<ul style="list-style-type: none"> <li>A statistically significant Wald test will suggest that ACEs differ in polygenic risk for mental health problems. Follow-up pairwise comparisons will show which ACEs differ. A non-significant Wald test would suggest the absence of evidence for differences between ACEs in polygenic risk for mental health problems.</li> <li>If the CIs for differences between ACEs in their associations with polygenic scores are within the equivalence bounds, this will suggest that there are not meaningful differences between these ACEs in polygenic risk for mental health problems. If the CIs do not fall within the equivalence bounds, this will suggest that the differences are of meaningful magnitude.</li> <li>Hypothesis 1c will be supported if (1) the Wald test is significant; (2) pairwise comparisons show that parental mental illness, parental substance abuse and parental criminality are associated with higher polygenic risk than other ACEs; and (3) the CIs for these differences are not within the equivalence bounds.</li> </ul>



**Table 1 (continued) | Summary of the study's research questions, hypotheses, power calculations, analyses and conditions for interpretation**

Question	Hypothesis	Sampling plan (including power analysis)	Analysis plan	Interpretations given to different outcomes
What proportion of the associations between ACEs and internalizing and externalizing problems is explained by observed polygenic scores for mental health problems?	(2a) Observed polygenic scores will explain a small proportion (between 5% to 20%) of the associations between ACEs and internalizing and externalizing problems.	$N=4,700$ gives 0.95 power to detect the proportion of the association between ACEs and mental health explained by observed polygenic scores in a structural equation model. For the aggregate model, $N=4,700$ will give a power of 1.00 to detect an average proportion of 5% (of the association between ACEs and mental health explained by polygenic scores).	<ul style="list-style-type: none"> <li>Use structural equation models (Fig. 5c) to test whether the associations between each ACE and each mental health outcome are mediated by polygenic scores (statistically equivalent to testing confounding).</li> <li>Calculate the proportion of the association between the ACE and the mental health outcome explained by the polygenic scores.</li> <li>Pool the results in an aggregate model to assess the average proportion of the associations between ACEs and mental health outcomes explained by observed polygenic scores.</li> <li>Repeat the analyses using negative-control polygenic scores.</li> </ul>	<ul style="list-style-type: none"> <li>The average proportion of associations between ACEs and mental health outcomes explained by observed polygenic scores will be interpreted as follows, broadly in line with guidance for interpreting effect sizes:<sup>123</sup> <ul style="list-style-type: none"> <li>&lt;5%, 'very small'</li> <li>5–20%, 'small'</li> <li>20–40%, 'moderate'</li> <li>&gt;40%, 'large'</li> </ul> </li> <li>Hypothesis 2a will be supported if (1) polygenic scores for mental health problems explain, on average, between 5% and 20% of the associations, and (2) the average proportion of the association explained by negative-control polygenic scores is not significantly different from zero.</li> </ul>
What proportion of the associations between ACEs and internalizing and externalizing problems is explained by polygenic scores that capture additional heritability in mental health problems?	(2b) Polygenic scores that capture SNP heritability in internalizing and externalizing problems will explain a moderate proportion (between 20% to 40%) of the associations between ACEs and these outcomes.	$N=4,700$ gives 1.00 power to detect the proportion of the association between ACEs and mental health explained by increasingly powerful polygenic scores in a structural equation model.	<ul style="list-style-type: none"> <li>Use a structural equation model (Fig. 5b) to test whether the associations between each ACE and each mental health outcome are mediated by polygenic scores capturing SNP heritability in the outcome.</li> <li>Estimate the model from a correlation matrix, modified to reflect additional genetic variance captured in the outcome<sup>27/24</sup> and ACE according to the ratio observed based on the observed polygenic scores.</li> <li>Pool the results in an aggregate model to assess the average proportion of the associations between ACEs and mental health outcomes explained by polygenic scores capturing SNP heritability.</li> </ul>	<ul style="list-style-type: none"> <li>The proportion of associations explained by polygenic scores capturing SNP-based heritability will be interpreted as specified above.</li> <li>Hypothesis 2b will be supported if polygenic scores capturing SNP-based heritability explain between 20% and 40% of the associations between ACEs and mental health outcomes on average.</li> </ul>


If our findings differed between ALSPAC and the ABCD Study, we proposed to interpret this as reflecting (1) differences between countries (the United Kingdom (ALSPAC) versus the United States (ABCD)) or (2) differences between historical periods (as the ALSPAC participants were born in 1991–1992 and the ABCD participants were born in 2006–2008). Differences in results between cohorts are less likely to be due to polygenic scores (as the same GWAS summary statistics will be used for both cohorts), ACE measures (as both cohorts used similar questionnaires reported by parents and children), mental health measures (as both cohorts used similar parent-reported questionnaires) and timing of assessments (as ACEs were assessed from birth to age nine or ten in both cohorts, and mental health was assessed at age ten in ALSPAC and age nine or ten in the ABCD). Note that the ABCD Study was not originally included in the Stage 1 pre-registration, but we used it because the original replication cohort (CATSS) was not accessible after Stage 1 acceptance (detailed in the Methods, 'Change in replication cohort').

There was no evidence in ALSPAC to suggest that the average polygenic risk for mental health problems differed across ACEs (Wald-test  $F(5, 5,319), 1.07; P = 0.37$ ). Furthermore, equivalence tests suggested that the majority of ACEs were associated with similar polygenic risk of mental health problems, as the 90% CIs for the differences between most ACEs fell inside the equivalence bounds (–0.05 to 0.05 on the log odds ratio scale; Fig. 4a).

**ABCD.** Similar to ALSPAC, in the ABCD cohort, the average polygenic risk for mental health problems was not significantly different across ACEs (Wald-test  $F(5, 246,200), 2.00; P = 0.08$ ). Equivalence tests also suggested that the majority of ACEs were associated with equal polygenic risk of mental health problems, as the 90% CIs for most differences between ACEs fell inside the equivalence bounds (Fig. 4b). The findings from both cohorts therefore did not support the hypothesis that parental mental illness, parental substance abuse and parental criminality would be associated with higher polygenic risk for mental health problems than other ACEs.

### Hypothesis 2a: what proportion of the associations between ACEs and internalizing and externalizing problems is explained by observed polygenic scores for mental health problems?

**ALSPAC.** To test genetic confounding, we next examined the proportion of the associations between ACEs and childhood mental health problems that were explained by polygenic scores for mental health problems (depression, anxiety, bipolar disorder, autism, ADHD, anti-social behaviour, alcohol use disorder and schizophrenia), using a structural equation model (Fig. 5c). In ALSPAC, polygenic scores for mental health problems explained a very small average proportion of the associations between ACEs and internalizing problems at age ten (4.4%; 95% CI, 1.9–6.8%;  $P = 0.0004$ ). These polygenic scores also explained a small average proportion of the associations between ACEs and externalizing problems at age ten (5.8%; 95% CI, 3.4–8.2%;  $P = 3.18 \times 10^{-6}$ ). The results for associations between specific ACEs and internalizing and externalizing problems are shown in Fig. 6a,b (red points) and Supplementary Table 2a. In contrast, negative-control polygenic scores for handedness and cataracts did not explain any part




**Fig. 1 | Associations between polygenic scores and ACEs in ALSPAC. a,** Associations between polygenic scores for mental health problems and ACEs. **b,** Associations between negative-control polygenic scores and ACEs. The data are presented as odds ratios  $\pm$  95% CIs, obtained from logistic regression models.

The *P* values for individual associations between polygenic scores and ACEs are from two-sided tests and are false discovery rate corrected. The sample size for the ALSPAC analyses was  $N = 6,411$ .

of the associations between ACEs and internalizing problems (average proportion, 0.0%; 95% CI,  $-0.6\%$  to  $0.5\%$ ;  $P = 0.91$ ) or externalizing problems (average proportion,  $-0.1\%$ ; 95% CI,  $-0.5\%$  to  $0.4\%$ ;  $P = 0.77$ ).

**ABCD.** Similar to ALSPAC, in the ABCD Study, polygenic scores for mental health problems explained a very small average proportion of the associations between ACEs and internalizing problems at age nine




**Fig. 2 | Associations between polygenic scores and ACEs in the ABCD Study.**  
**a**, Associations between polygenic scores for mental health problems and ACEs.  
**b**, Associations between negative-control polygenic scores and ACEs. The data are presented as odds ratios  $\pm$  95% CIs, obtained from logistic regression models.

The *P* values for individual associations between polygenic scores and ACEs are from two-sided tests and are false discovery rate corrected. The sample size for the ABCD analyses was  $N = 4,996$ .

or ten (3.0%; 95% CI, 1.0–4.9%;  $P = 0.003$ ) and a small average proportion of the associations between ACEs and externalizing problems at age nine or ten (5.0%; 95% CI, 3.3–6.7%;  $P = 6.38 \times 10^{-9}$ ). The results for

associations between specific ACEs and internalizing and externalizing problems are shown in Fig. 6c,d (red points) and Supplementary Table 2b. Negative-control polygenic scores did not explain any of




**Fig. 3 | Pairwise differences between polygenic scores in their association with ACEs. a, b.** Differences between polygenic scores in their association with ACEs in ALSPAC (a) and in the ABCD Study (b). The data are presented as log odds differences  $\pm$  90% CIs. Positive effect sizes reflect the first labelled polygenic

score having a stronger positive average association with ACEs than the second polygenic score. The red dashed lines show the pre-specified equivalence bounds. The *P* values are for the difference in log odds ratio between polygenic scores (two-sided tests). *N* = 6,411 in ALSPAC and *N* = 4,996 in the ABCD Study.

the associations between ACEs and internalizing problems (average proportion, 0.0%; 95% CI, -0.3% to 0.4%; *P* = 0.90) or externalizing problems (average proportion, 0.1%; 95% CI, -0.3% to 0.5%; *P* = 0.56).

Taken together, these findings broadly support the hypothesis that observed polygenic scores account for a small proportion (defined as 5–20%) of the average association between ACEs and mental health






**Fig. 4 | Pairwise differences between ACEs in their association with polygenic risk for mental health problems. a, b,** Differences between ACEs in their association with polygenic risk for mental health problems in ALSPAC (**a**) and in the ABCD Study (**b**). The data are presented as log odds differences  $\pm$  90% CIs (two-sided tests). Positive effect sizes reflect the first labelled ACE having

a stronger positive association with pooled polygenic risk for mental health problems; negative effect sizes reflect the second labelled ACE having a stronger positive association with pooled polygenic risk for mental health problems. The red dashed lines show the pre-specified equivalence bounds.  $N = 6,411$  in ALSPAC and  $N = 4,996$  in the ABCD Study.

problems, although the proportion captured for internalizing problems was slightly smaller (<5%) than hypothesized.

**Hypothesis 2b: what proportion of the associations between ACEs and internalizing and externalizing problems is explained by latent polygenic scores capturing additional heritability in mental health problems?** Because polygenic scores for mental health problems

captured only a very small proportion of variance in internalizing problems (<1%) and externalizing problems (1.6%; Supplementary Table 3), the previous analyses probably underestimated the magnitude of genetic confounding. To address this, we conducted a genetic sensitivity analysis<sup>27</sup>, which estimates genetic confounding using latent polygenic scores capturing SNP heritability in outcomes (6% and 9% for internalizing and externalizing problems, respectively<sup>33,34</sup>).




**Fig. 5 | Structural equation models to estimate the genetic contribution to the associations between ACEs and mental health. a–c.** In all diagrams, MH represents the mental health outcome (for example, internalizing problems or externalizing problems), and PGS represents the polygenic score, with one polygenic score shown in **a** and **b**, and all eight polygenic scores (PGS\_1 to PGS\_8) shown in **c**. **a** depicts the underlying conceptual model, in which the polygenic score is treated as a confounder. **b** depicts the statistical model to calculate the genetic confounding effect, in which the polygenic score is treated as a mediator. Note that conceptually, the polygenic score cannot be a mediator in the association between ACEs and mental health because genetic variants are set

at conception and do not change throughout the lifespan. However, statistically, we can estimate the genetic confounding effect by treating the polygenic score as a mediator and calculating the indirect effect of ACEs on mental health through the polygenic score. **c** represents the statistical model in which all eight polygenic scores are included as mediators. Though not depicted in the figure to aid clarity, we account for correlations between polygenic scores in the model. Paths are labelled as ‘a’ (for the association between polygenic score(s) and ACEs), ‘b’ (for the association between polygenic score(s) and mental health), and ‘cp’ (for the adjusted association between ACEs and mental health).

**ALSPAC.** In ALSPAC, the genetic sensitivity analysis suggested that a large average proportion of the associations between ACEs and internalizing problems was explained by genetic confounding (90.3%; 95% CI, 80.1–100%;  $P = 1.76 \times 10^{-68}$ ), with proportions ranging from 56.9% for parental mental illness to 100% for domestic violence, parental substance abuse, criminality and separation (Supplementary Table 4a and Fig. 6a (blue points)). Similarly, a large average proportion of the associations between ACEs and externalizing problems was accounted for by genetic confounding (76.5%; 95% CI, 59.5–93.6%;  $P = 1.43 \times 10^{-18}$ ), with proportions ranging from 49.4% for child maltreatment to 100% for parental substance abuse (Supplementary Table 4a and Fig. 6b (blue points)). However, CIs could not be reliably computed for some individual estimates (where the genetic confounding

effect explained 100% of the associations; Supplementary Table 4 and Fig. 6a,b), and such estimates should therefore be interpreted with caution.

**ABCD.** In the ABCD Study, the genetic sensitivity analysis suggested that genetic confounding accounted for a large average proportion of the associations between ACEs and internalizing problems (68.6%; 95% CI, 55.5–81.7%;  $P = 1.07 \times 10^{-24}$ ), with proportions ranging from 22% for parental mental illness to 100% for parental criminality and separation (Supplementary Table 4b and Fig. 6c (blue points)). Similarly, a large average proportion of the associations between ACEs and externalizing problems was captured by genetic confounding (60.3%; 95% CI, 48.7–71.9%;  $P = 2.22 \times 10^{-24}$ ), with proportions ranging from 30.2% for parental mental illness to 100% for



**Fig. 6 | Genetic confounding of the associations between ACEs and internalizing and externalizing problems.** **a**, The associations between ACEs and internalizing problems in ALSPAC. **b**, The associations between ACEs and externalizing problems in ALSPAC. **c**, The associations between ACEs and internalizing problems in the ABCD Study. **d**, The associations between ACEs and externalizing problems in the ABCD Study. The data are presented as standardized  $\beta$  coefficients  $\pm$  95% CIs for associations between ACEs and mental

health outcomes, before accounting for polygenic scores (yellow points) and after accounting for (1) observed polygenic scores for mental health problems (red points) and (2) a latent polygenic score capturing SNP heritability in the outcome (blue points). The tests were two-sided. Confidence intervals could not be reliably computed for associations attenuated to zero, and therefore these estimates should be interpreted with caution.  $N = 6,411$  in ALSPAC and  $N = 4,996$  in the ABCD Study.

parental criminality (Supplementary Table 4b and Fig. 6d (blue points)). These results indicate that the proportion of the associations between ACEs and mental health explained by genetic confounding is greater than the moderate amount (between 20% to 40%) hypothesized.

## Robustness analyses

To assess the robustness of our results, we conducted three sets of analyses. First, because reliable CIs could not be computed for some results in the genetic sensitivity analysis (Supplementary Table 4), we were concerned that these results might have biased the pooled estimates of genetic confounding. We therefore re-estimated the average proportions of genetic confounding after excluding these results with unreliable CIs. The average proportion of the associations between ACEs and internalizing problems explained by genetic confounding was attenuated but still large (ALSPAC: 70.8%; 95% CI, 40.4–100%;  $P = 4.88 \times 10^{-6}$ ; ABCD: 52.9%; 95% CI, 33.2–72.6%;  $P = 1.33 \times 10^{-7}$ ). This was also the case for the associations between ACEs and externalizing problems (average proportion genetically confounded: 71.8% in ALSPAC (95% CI, 51.4–92.3%;  $P = 6.01 \times 10^{-12}$ ) and 52.4% in the ABCD Study (95% CI, 38.5–66.3%;  $P = 1.66 \times 10^{-13}$ )).

Second, we repeated all analyses in the complete case samples from ALSPAC and ABCD ( $N = 4,106$  and  $N = 4,662$ , respectively) and observed largely consistent results (Supplementary Results 1).

Third, because we constructed the polygenic scores for bipolar disorder from an updated GWAS<sup>35</sup> that differed from the older GWAS<sup>36</sup>

that we proposed to use in the Stage 1 pre-registration (Supplementary Table 5), we repeated the analyses with polygenic scores for bipolar disorder derived from the pre-registered GWAS. The results were consistent with the main findings (Supplementary Results 2).

## Discussion

This Registered Report examined the genetic contribution to the associations between ACEs and mental health, in two prospective cohorts of over 11,000 children from the United Kingdom and the United States. Our findings provide insight into gene–environment correlations and genetic confounding of the relationship between ACEs and mental health.

With regard to gene–environment correlations, we made three key findings. First, children with higher polygenic scores for mental health problems had an elevated risk of ACEs. This gene–environment correlation was small but robust (replicating across cohorts), and negative-control polygenic scores were not associated with ACEs. This supports our hypothesis and other (largely non-pre-registered) research showing that polygenic scores for mental health problems are associated with greater risk of exposure to childhood adversities<sup>21–25,37,38</sup>. Importantly, this does not suggest that exposure to ACEs is determined by genes, is the fault of the child or is not preventable. Rather, the findings suggest that children with higher genetic liability to mental health problems are on average slightly more likely to experience ACEs. However, ACEs are influenced by many factors (including

social and environmental risks<sup>39</sup>) and can be effectively prevented through social interventions<sup>40,41</sup>.

Second, in both cohorts, polygenic scores for ADHD, depression and schizophrenia were more strongly associated with risk of exposure to ACEs than some other polygenic scores (particularly alcohol use and autism). In the ABCD Study, polygenic scores for antisocial behaviour and bipolar disorder also showed stronger associations with ACEs. These results do not support our hypothesis that there would be no differences between polygenic scores, but they broadly align with evidence showing that polygenic scores for ADHD, depression and schizophrenia are independently associated with child maltreatment<sup>37</sup> and bullying victimization<sup>23</sup>, while polygenic scores for other psychiatric disorders are not. Nevertheless, this finding should be interpreted with caution, as it may reflect differences in the predictive power of polygenic scores, given that the most predictive polygenic scores tended to be based on large GWAS samples and have higher SNP heritability (Supplementary Table 5). Alternatively, such differences might be because genetic liabilities to ADHD, depression and schizophrenia have greater causal effects on exposure to ACEs than other genetic liabilities (for example, because of stronger passive or evocative gene–environment correlations).

Third, different ACEs were associated with similar genetic risk of mental health problems in both cohorts. This was contrary to our hypothesis that parental mental illness, parental substance abuse and parental criminality would be associated with greater (child) genetic risk of psychopathology than other ACEs, due to intergenerational genetic transmission. While these ACEs (originating in the parents) are likely to be linked to child genetic risk of psychopathology largely via passive gene–environment correlation, other ACEs might be related to genetic risk of psychopathology in part via evocative gene–environment correlation. Indeed, evidence suggests that children at genetic risk for externalizing problems are more likely to experience negative parenting via evocative gene–environment correlation<sup>16,17</sup>, and evocative gene–environment correlations were found to partly underlie risk of maltreatment<sup>42</sup>. Importantly, evidence of such evocative gene–environment correlations does not mean that children are to blame for ACEs—rather, parents are responsible for protecting them and reacting to their behaviour in an appropriate way<sup>42</sup>. Evidence of evocative gene–environment correlation would therefore highlight the importance of family-based interventions to help parents respond effectively to their children's behaviour and support children with vulnerabilities.

With regard to genetic confounding, we first found that observed polygenic scores for mental health problems explained on average 3–5% of the associations between ACEs and internalizing problems and 5–6% of the associations between ACEs and externalizing problems. In contrast, negative-control polygenic scores did not account for any of the associations between ACEs and mental health problems. These results broadly support our hypothesis that a small proportion (defined as 5–20%) of the associations between ACEs and mental health would be captured by polygenic scores for psychopathology. However, these results probably underestimate the magnitude of genetic confounding, as the polygenic scores for mental health problems captured only a very small amount of variation (<1% and <1.6%, respectively) in internalizing and externalizing outcomes.

To address this, we conducted a genetic sensitivity analysis<sup>27</sup> using latent polygenic scores capturing SNP heritability in internalizing and externalizing problems (6% and 9%, respectively). This analysis suggested that genetic confounding accounted for a large average proportion of the associations between ACEs and internalizing and externalizing problems, in both cohorts. However, we caution against drawing strong conclusions based on the specific proportions of genetic confounding, for three reasons. First, the precise magnitude of genetic confounding varied between cohorts, and the point estimates were greater in ALSPAC than in the ABCD Study. This is likely to be because ACEs had weaker associations with mental health problems

in ALSPAC (Fig. 6), increasing the likelihood that genetic confounding could account for larger proportions of the associations. In contrast, the magnitude of associations between polygenic scores and ACEs did not differ between cohorts (Supplementary Table 3). Second, CIs could not be reliably estimated for some specific estimates of genetic confounding, in particular for proportions of 100% (largely observed for internalizing outcomes in ALSPAC), suggesting that these proportions may not be reliable. Third, the genetic sensitivity analysis is best suited for scenarios in which the polygenic score strongly and specifically predicts the outcome<sup>27</sup>. Given the lack of available GWASs for child internalizing and externalizing problems, we used polygenic scores for adult psychiatric disorders, which showed similar or stronger-magnitude associations with ACEs than with child internalizing and externalizing problems (Supplementary Table 3). The use of a polygenic score that is not specific to the outcome may result in overestimated genetic confounding (discussed in detail in the Supplementary Discussion). It will therefore be important to repeat the genetic sensitivity analysis with polygenic scores derived from future GWASs of child internalizing and externalizing problems, when available.

Despite our cautious interpretation surrounding specific estimates of genetic confounding, the overall pattern of results supports findings from other genetically informed designs with different assumptions and sources of bias. For example, we found that child maltreatment was largely associated with internalizing and externalizing problems, independent of genetic confounding. This is consistent with evidence of causal effects of maltreatment on psychopathology from Mendelian randomization<sup>42</sup>, co-twin control<sup>43</sup> and other quasi-experimental studies<sup>44</sup>. We also found that parental mental illness was associated with internalizing and externalizing problems independent of genetic confounding, which supports evidence from children-of-twins and adoption studies<sup>45–47</sup>. In contrast, we found that parental substance abuse, parental criminality and parental separation were predominantly associated with internalizing and externalizing problems via genetic confounding. Notably, similar genetically confounded associations with psychopathology have also been reported for parental substance abuse in children-of-twins<sup>48,49</sup> and adoption studies<sup>50</sup>, for parental criminality in an adoption study<sup>51</sup>, and for parental separation in some<sup>52</sup> (though not all<sup>53</sup>) children-of-twins studies.

We acknowledge some limitations. First, it is possible that the observed associations might be inflated by reporting bias, as parents with genetic liability to psychopathology might be more likely to perceive ACEs<sup>54</sup> and child psychopathology, as well as transmit genetic liability to their children. Future studies using different informants to measure ACEs and psychopathology (for example, from objective records to more subjective self-reports) are needed to map the impact of reporting biases on observed gene–environment correlations<sup>38,55</sup> and estimates of genetic confounding. Second, ALSPAC and the ABCD Study differed in various ways, such as the country of origin (the United Kingdom versus the United States), the historical context (born in 1991–1992 versus 2006–2008) and the prevalence of ACEs (for example, higher rates of maltreatment and parental criminality in ALSPAC, perhaps due to repeated assessments (versus a single assessment in the ABCD Study)). The ABCD analysis is therefore not a direct replication of the ALSPAC findings, and any differences in findings might be attributable to these cohort differences. However, the overall pattern of results was consistent across both cohorts, indicating that the findings are robust. Third, as discussed, it was not possible to infer whether differential associations between polygenic scores for psychiatric disorders and ACEs reflected specific genetic liabilities underlying risk of ACEs, or differences in the predictive power of polygenic scores (for example, due to different GWAS discovery sample sizes). Fourth, our analysis was limited to individuals of European descent to match the ancestry of the GWAS discovery samples<sup>56</sup>. Once large-scale trans-ancestry GWASs become available, it will be important to replicate our findings in ancestrally diverse samples to ensure greater representation



in research<sup>57</sup>. Finally, these findings reflect average population effects and do not preclude the existence of causal effects of certain ACEs (for example, parental substance abuse, parental criminality and parental separation) on child psychopathology in subpopulations.

Our findings have implications for future research. First, to understand the extent to which the observed gene–environment correlations are passive or evocative, future studies should integrate polygenic scores into family-based designs (for example, parent–offspring trios)<sup>30</sup>. Second, to the extent that ACEs are causal risk factors for psychiatric disorders, genetic variants influencing exposure to ACEs (that is, gene–environment correlations) might be captured in GWASs of those disorders<sup>55,58</sup>. If GWASs of ACEs were to become available, future genetically informed studies could test whether this reflects one of the origins of the observed associations between polygenic scores for psychiatric disorders and ACEs. Third, the gene–environment correlations observed here challenge the assumption in gene–environment interaction studies that genetic influences on psychopathology and ACEs are independent<sup>13,59</sup>. Future gene–environment interaction studies on childhood adversity and psychopathology should adopt methods that account for such gene–environment correlations to mitigate bias<sup>13,59</sup>. Lastly, this study suggests that non-genetically informative studies are likely to overestimate the causal contribution of ACEs to mental health problems. To provide accurate estimates of the causal effects of ACEs, future studies should employ methods that account for genetic confounding and triangulate evidence across methods with different assumptions and sources of potential bias<sup>60,61</sup>. More broadly, combining genetically informed methods with open science practices (for example, pre-registration and Registered Reports) will help address multiple sources of bias (for example, genetic confounding, researcher bias<sup>62</sup> and publication bias<sup>63</sup>) to enable the collection of rigorous evidence on the effects of ACEs on health.

Our findings also have implications for interventions. Because child maltreatment and parental mental illness were largely associated with child psychopathology independent of genetic influences, preventing these ACEs may not only improve child welfare and family functioning but also help prevent child psychopathology in the population. Such interventions could include parenting support programmes to prevent maltreatment<sup>40</sup>, as well as more accessible psychiatric treatment for parents with mental health problems. In contrast, preventing ACEs with entirely genetically confounded effects is unlikely to substantially impact child psychopathology at the population level, although such interventions are likely to have other important positive outcomes (for example, for child welfare, family functioning and potentially physical health<sup>64–67</sup>). Furthermore, because polygenic scores for mental health problems accounted for at least part of the associations between all ACEs and psychopathology, strategies that address heritable psychiatric vulnerabilities in children exposed to ACEs (for example, through skill building<sup>68</sup> or fostering positive family interaction) should reduce their risk of developing psychopathology.

## Methods

### Change in replication cohort

As stated in our Stage 1 protocol (<https://doi.org/10.6084/m9.figshare.13580777.v1>), this Registered Report originally proposed to replicate findings from ALSPAC in the CATSS dataset and not the ABCD Study. However, after receiving Stage 1 in-principle acceptance, we experienced two unforeseen issues that meant that we could not use the CATSS dataset: (1) the data could not be accessed in a timely manner because of COVID-related travel restrictions for Sweden, and (2) data access restrictions from the Swedish National Board of Health and Welfare meant that we could not use national registry data to measure ACEs, as originally proposed. We therefore proposed and received permission to use the ABCD Study as an alternative replication sample to CATSS (after peer review of the protocol for analysis on ABCD). Importantly, we had not accessed data from either CATSS

or the ABCD Study at the time at which we proposed to use the ABCD Study, so we were blind to the results in these cohorts (though we had undertaken analysis in ALSPAC). To provide transparency about what we intended to do in the Stage 1 protocol, we report all details about the CATSS dataset in Supplementary Methods 1.

### Ethics information

Ethics approval for ALSPAC was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Informed consent for the use of data collected via questionnaires and clinics was obtained from the participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). Ethics approval for the ABCD Study was given by a central Institutional Review Board at the University of California, San Diego, and in some cases by individual site institutional review boards (for example, Washington University in St. Louis)<sup>69</sup>. Parents or guardians provided written informed consent after the procedures had been fully explained, and children assented before participation in the study<sup>70</sup>.

### Design

ALSPAC and the ABCD Study are prospective longitudinal cohort studies. A description of these datasets and their measures is below.

### ALSPAC

**Sample.** The ALSPAC is a longitudinal study of children born in the United Kingdom in 1991–1992. ALSPAC sought to recruit all pregnant women in the former county of Avon, United Kingdom, with an expected due date between 1 April 1991 and 31 December 1992. The initial sample consisted of children of 14,541 mothers. Children have been followed up and assessed repeatedly across development through questionnaires, face-to-face interviews, and physical and psychological assessments (including biological assays)<sup>71–73</sup>. The study website contains details of all the data that are available through a fully searchable data dictionary and variable search tool (<http://www.bristol.ac.uk/alspac/researchers/our-data/>). The analytic sample was 49% female.

**Measures.** ACEs. We examined six ACEs: maltreatment, domestic violence, parental mental illness, parental substance abuse, parental separation and parental criminality. These experiences all involve adversity in the family context and were included in the Centers for Disease Control and Prevention Adverse Childhood Experiences Study<sup>3,74</sup> and the World Health Organization ACE international questionnaire<sup>75</sup>. In ALSPAC, these ACEs were assessed prospectively through parent and child reports via questionnaires at multiple assessment phases from birth to age nine years (115 months). Details of these assessments are provided in Supplementary Table 6. We derived binary measures reflecting exposure to each ACE according to the definitions shown in Supplementary Table 6 and recommended by a previous ALSPAC Data Note on ACE measures<sup>76</sup>. Note that subtypes of maltreatment (neglect and physical, sexual and emotional abuse) were combined into a single measure due to low individual prevalence and high co-occurrence<sup>76,77</sup>. Measures of each ACE were derived for participants with responses to  $\geq 50\%$  of the questions assessing that ACE between birth and age nine years. We used multiple imputation to estimate ACE exposure in participants with responses to  $< 50\%$  but  $\geq 10\%$  of questions assessing the ACE (see Supplementary Methods 2 for further details of the multiple imputation procedure).

**Mental health problems.** Internalizing problems and externalizing problems were assessed through parent reports on the Development and Well-Being Assessment (DAWBA)<sup>78</sup> at age ten years. The DAWBA is a semi-structured interview assessing multiple domains of child psychopathology with good validity<sup>78</sup> and reliability<sup>79</sup>. Items from the DAWBA used to derive the mental health measures are presented in Supplementary Table 7.

Internalizing problems were assessed through modules on separation anxiety (11 items, scale from 0 to 20), social anxiety (6 items, scale from 0 to 12), generalized anxiety (15 items, scale from 0 to 28) and major depression (15 items, scale from 0 to 15). We derived one overall measure of internalizing problems through the following steps. First, we calculated the mean for each of the four modules (separation anxiety, social anxiety, general anxiety and major depression) for participants with data for  $\geq 50\%$  of the items, before standardizing the scores. Next, we summed the scores across the anxiety subscores and standardized the measure, so we have one overall measure of anxiety and one for major depression. Last, we summed these anxiety and depression scores before standardizing the overall single measure.

Externalizing problems were assessed through modules on hyperkinesis/ADHD (18 items, scale from 0 to 36) and conduct/oppositional disorders (17 items, scale from 0 to 34). To derive one overall measure of externalizing problems, we first calculated the mean for each of the two modules for participants with data for  $\geq 50\%$  of the items. We then standardized the two scores and summed them before standardizing the overall single measure.

**Genotyping and quality control.** ALSPAC children have been genotyped using the Illumina HumanHap550 quad chip genotyping platforms by 23andMe subcontracting the Wellcome Trust Sanger Institute and the Laboratory Corporation of America. Quality control (QC) was carried out in PLINK<sup>80</sup>, adhering to the standard guidelines<sup>81,82</sup>, which have been previously used effectively for the analysis of genetic data in ALSPAC<sup>21,23,83</sup>. Specifically, samples were removed on the basis of (1) low call rate (poor DNA quality), (2) outlying heterozygosity across autosomes, (3) relatedness (based on identity by state), (4) gender mismatches and (5) non-European population ancestry. SNPs were removed on the basis of (1) low call rate, (2) extreme deviation from Hardy–Weinberg equilibrium and (3) low minor allele frequency. Further details are provided in Supplementary Table 8.

**Polygenic scores.** We derived polygenic scores for mental health problems—namely, major depressive disorder, anxiety disorder, bipolar disorder, autism, ADHD, antisocial behaviour, alcohol use disorder and schizophrenia. We selected these polygenic scores because they (1) index genetic liability to a range of mental health problems and (2) have been found to be associated with ACEs<sup>21–23,26</sup> and/or psychopathology in young people<sup>84–87</sup>. We also derived negative-control polygenic scores for traits with no known association with ACEs or mental health (namely, handedness and cataracts). All polygenic scores were generated using GWAS summary statistics that (1) were derived from European samples that did not include ALSPAC or ABCD participants (to avoid sample overlap) and (2) had  $N > 16,000$  in the discovery sample (to ensure adequate power). Supplementary Table 5 provides details of the GWAS summary statistics that were used to derive the polygenic scores.

In our Stage 1 protocol, we specified that if new, larger GWASs were published after submission, we would use the updated summary statistics to benefit from greater power (and report any such changes in the Stage 2 submission). Since the Stage 1 submission, new, larger GWASs were published for bipolar disorder<sup>35</sup> ( $N = 413,466$  versus  $N = 51,710$  in the original GWAS<sup>36</sup>) and antisocial behaviour problems<sup>88</sup> ( $N = 83,674$  versus  $N = 16,400$  in the original GWAS<sup>87</sup>), and so we derived polygenic scores from these updated summary statistics for our main analyses. For transparency, we also report the results using the originally pre-registered GWAS summary statistics<sup>36</sup> to derive the polygenic score for bipolar disorder. We did not do this using the older GWAS for antisocial behaviour<sup>87</sup>, as we realized that there was sample overlap for ALSPAC, which could have led to biased estimates<sup>89</sup>.

Polygenic scores were derived in PRSice software<sup>90,91</sup>, using the following method. First, SNPs from the participants were matched with SNPs reported in the GWAS summary statistics for each phenotype (for

example, each mental health problem). Clumping was conducted to remove SNPs in linkage disequilibrium ( $r^2 > 0.1$  within a 250-base-pair window). Next, we summed the alleles associated with the phenotype and weighted them by their effect sizes reported in the corresponding GWAS, to compute polygenic scores. We included all matched SNPs regardless of the nominal significance for their association with ACEs. To control for population stratification, we residualized the polygenic scores for the first ten principal components estimated from the genome-wide SNP data. To facilitate interpretability, all polygenic scores were standardized to have a mean of 0 and a standard deviation of 1.

### The ABCD Study

**Sample.** The ABCD Study is a prospective cohort of 11,878 children born in 2006–2008 and their parents from 21 sites in the United States. The 21 geographic locations of the ABCD research sites are nationally distributed and generally represent the range of demographic and socio-economic diversity of the US birth cohorts comprising the ABCD study population<sup>92</sup>. Full details on the recruitment strategy are available elsewhere<sup>93</sup>. Briefly, children aged nine to ten years were recruited through probability sampling of public and private elementary schools within the catchment areas of the 21 research sites. School selection was based on gender, race and ethnicity, socio-economic status, and urbanicity. The inclusion criteria were the child's age and attending a public or private elementary school within the catchment areas. The exclusion criteria for children were limited to not being fluent in English, having a parent not fluent in English or Spanish, major medical or neurological conditions, gestational age  $< 28$  weeks or birthweight  $< 1,200$  g, contraindications to MRI scanning, a history of traumatic brain injury, a current diagnosis of moderate/severe autism spectrum disorder, intellectual disability, schizophrenia, or alcohol/substance use disorder<sup>94</sup>. Assessments were made through in-person visits. This study used data from the baseline assessment (ages 9–10) and a one-year follow-up (ages 10–11) from ABCD Data Release 3.0. The analytic sample was 47% female.

**Measures.** ACEs. Consistent with the ALSPAC cohort, we assessed six ACEs (maltreatment, domestic violence, parental mental illness, parental substance abuse, parental separation and parental criminality) between birth and age nine to ten years. These ACEs have been assessed through parent and child reports from validated questionnaires at the baseline and one-year follow-up assessments<sup>95</sup>. The details of these assessments are reported in Supplementary Table 9. In brief, maltreatment was assessed using the parent-reported Kiddie-Structured Assessment for Affective Disorders and Schizophrenia module for post-traumatic stress disorder<sup>36,97</sup> (KSADS-PTSD; with eight items for physical, sexual and emotional abuse) and the Children's Report of Parental Behavioral Inventory<sup>98</sup> (with five items for neglect), consistent with previous studies<sup>42</sup>. Domestic violence was assessed using parent reports on the KSADS-PTSD and parent and child reports on the Family Environment Scale—Family Conflict Subscale<sup>99,100</sup>. Parental mental illness and substance abuse were assessed via parent reports on the Family History Assessment Module<sup>101</sup> and the Adult Self Report<sup>102,103</sup>. Parental criminality was assessed through parent reports on the Adverse Life Events Scale<sup>104</sup>, and parental separation was assessed through parent reports on the Demographic Survey. Measures of each ACE were derived for participants with responses to  $\geq 50\%$  of the questions assessing that ACE between birth and age nine to ten years.

**Mental health problems.** Internalizing problems and externalizing problems were assessed using parent reports on the Child Behavior Checklist (CBCL)<sup>105</sup> from the baseline assessment at age nine or ten. The CBCL is a 119-item, three-point scale questionnaire that measures problems occurring in the past six months, with excellent reliability

and validity<sup>106</sup>. Items from the CBCL used to derive the mental health measures are presented in Supplementary Table 10.

Internalizing problems were assessed through the anxious/depressed, withdrawn/depressed and somatic complaints subscales (32 items), as recommended previously<sup>107</sup>. Externalizing problems were assessed through the rule-breaking behaviour, aggressive behaviour and attention problems subscales (45 items). These subscales broadly map onto the DAWBA subscales used to assess internalizing and externalizing problems in ALSPAC, maximizing consistency between the samples. To derive composite scores of internalizing and externalizing problems, we summed the scores across the relevant items (for participants with data for >50% of the items) before standardizing the summary measures.

**Genotyping and QC.** Children from the ABCD Study have been genotyped from blood and saliva samples using the Affymetrix NIDA Smoke-Screen Array<sup>108</sup>. Sample preparation and genotyping was performed by Rutgers RUCDR. Initial QC was performed by the ABCD Data Analysis, Informatics & Resource Center following the Ricopili pipeline<sup>109</sup> (see Supplementary Table 8 for the details). Imputation was then performed on the genotype data using the TOPMed imputation server, following the pre-imputation steps instructed at <https://topmedimpute.readthedocs.io/en/latest/prepare-your-data/>. In line with previous ABCD studies<sup>42,110,111</sup>, we performed additional QC on the imputed genetic data (Supplementary Table 8), including removing samples with high relatedness and non-European population ancestry and removing SNPs that deviate from Hardy–Weinberg equilibrium, have a low minor allele frequency and have poor imputation quality.

**Polygenic scores for mental health problems.** We derived polygenic scores for mental health problems and negative controls using the same procedure as described for the ALSPAC participants. We also residualized the polygenic scores for genotyping batch, as the ABCD participants have been genotyped in multiple batches.

### Analysis plan

We conducted all statistical analyses in R v.3.6.2 (ref.<sup>112</sup>), focusing first on the ALSPAC cohort before testing whether the findings replicate in the ABCD Study (originally planned to be the CATSS dataset). Below we describe the statistical analyses that we used to test each of our aims and hypotheses (summarized in Table 1). The multiple imputation procedure for the ALSPAC and ABCD data is described in the Supplementary Methods 2 and 3.

### Aim 1: investigate whether children with genetic liability to mental health problems are more likely to be exposed to ACEs.

**Hypothesis 1a.** We first tested the associations between polygenic scores for mental health problems and ACEs through logistic regression models. We ran separate models for each ACE and each polygenic score (including negative controls). Log odds coefficients were exponentiated to obtain odds ratios reflecting the odds of exposure to each ACE per one-standard-deviation increase in the polygenic score. These models (and all further analyses) controlled for sex and were two-sided. To account for multiple testing, we computed false-discovery-rate-corrected *P* values<sup>113</sup>.

To obtain a single effect size reflecting the average association between polygenic scores for mental health problems and ACEs, we pooled the results across all logistic regression models within each cohort. This procedure was performed using the `agg` function in the `MAd` package<sup>114</sup>, which accounts for correlations across effect sizes (as a function of the same sample). We pooled two sets of results: (1) for associations between polygenic scores for mental health problems and ACEs, and (2) for associations between negative-control polygenic scores and ACEs.

Because null hypothesis significance testing cannot enable substantive interpretation of statistically non-significant findings,

we conducted an equivalence test<sup>115</sup> to quantify support for the null hypothesis. This involves assessing whether the 90% CIs for the effect size lie entirely inside pre-specified equivalence bounds indexing the smallest effect size of interest. If the CIs lie inside the equivalence bounds, the effect size can be said to be no more than trivially small. If the CIs are not inside the equivalence bounds, the effect size can be said to be of meaningful magnitude. Note that the 90% (rather than 95%) CIs are used, corresponding to  $(1 - 2\alpha) \times 100\%$ , because the effect size is tested against two equivalence bounds separately (that is, the upper and lower bounds).

To select equivalence bounds, we followed guidance to use the lower CI of a meta-analytic estimate of the effect of interest<sup>115,116</sup>. Because no such meta-analysis exists, we conducted a meta-analysis of all studies<sup>21–26</sup>, to our knowledge, that have tested the association between polygenic scores for mental health problems (see [https://osf.io/2uc4p/?view\\_only=2d9afc1b072b4507ba11ba8771aaab62](https://osf.io/2uc4p/?view_only=2d9afc1b072b4507ba11ba8771aaab62) for the code and results). The pooled association between polygenic scores for mental health problems and ACEs was OR = 1.10 (95% CI, 1.06–1.14). We thus selected equivalence bounds of 0.94–1.06 on the odds ratio scale, because 1.06 was the lower CI of the meta-analytic effect and 0.94 is the equal delta of 1.06 in the opposite direction on the log odds ratio scale.

We proposed to infer support for Hypothesis 1a (that children with greater genetic liability to mental health problems would have a higher risk of experiencing ACEs) if (1) the pooled odds ratio for the association between polygenic scores for mental health problems and ACEs was greater than 1 and statistically significant, (2) the 90% CI for this effect was not within the equivalence bounds, and (3) the pooled odds ratio for the association between negative-control polygenic scores and ACEs was non-significant. The interpretation of alternative patterns of results is shown in Table 1.

**Hypothesis 1b.** We next tested whether polygenic scores for certain mental health problems are more strongly associated with ACEs than other polygenic scores. To do so, we first used a structural equation model to estimate the association between each polygenic score and each ACE (Supplementary Fig. 1). This model accounted for correlations between polygenic scores, allowing us to estimate the independent effect of each polygenic score on each ACE. From the model, we calculated the average effect of each polygenic score across all ACEs, estimated as  $\frac{(a_1+a_2+\dots+a_n)}{6}$  for the first polygenic score (PGS\_1 in Supplementary Fig. 1),  $\frac{(b_1+b_2+\dots+b_n)}{6}$  for the second polygenic score (PGS\_2 in Supplementary Fig. 1) and so forth for each polygenic score. These analyses were conducted using the `lavaan` package<sup>117</sup>, using the WLSMV estimator with robust standard errors, and the 'ordered' argument (for the binary ACE endogenous variables). To aid interpretation, we converted the resulting probit coefficients into odds ratios using the formula  $\exp(\text{probit } \beta \times 1.8)$ <sup>118,119</sup>. We then conducted a Wald test (using the `lavTestWald` function) to test whether the average effect of each polygenic score on all ACEs varied across polygenic scores. If the Wald test was statistically significant ( $P < 0.05$ ), we conducted pairwise comparisons to assess which polygenic scores differ in prediction of ACEs.

Lastly, we tested for statistical equivalence between different polygenic scores in their average association with ACEs by (1) calculating differences in the average effects of polygenic scores, expressed as (log) odds ratios<sup>120</sup>, and (2) assessing whether the 90% CIs for these differences fall within equivalence bounds of –0.10 to 0.10. We selected these equivalence bounds by identifying the smallest effect size that we have 95% power to detect (log odds difference, 0.10; 95% CI, 0.07–0.13). This approach is recommended in the absence of a strong theoretical justification for equivalence bounds<sup>115</sup>, which was the case because no previous study has formally tested differences between polygenic scores in the association with ACEs.

We proposed to infer support for Hypothesis 1b (that polygenic scores for different mental health problems would equally predict



exposure to ACEs) if the Wald test was statistically non-significant ( $P > 0.05$ ) and the 90% CIs for the differences between polygenic scores (in their associations with ACEs) fell within the equivalence bounds. The interpretation of alternative patterns of results is shown in Table 1.

**Hypothesis 1c.** Next, we tested whether some ACEs were associated with higher polygenic risk of mental health problems than other ACEs. To do so, we used the same structural equation model as estimated for Hypothesis 1b (shown in Supplementary Fig. 1) and calculated the average effect of all polygenic scores for mental health problems on each ACE, estimated as  $\frac{(a_1+b_1+\dots+h_1)}{8}$  for the first ACE (ACE\_1),  $\frac{(a_2+b_2+\dots+h_2)}{8}$  for the second ACE (ACE\_2) and so forth for each ACE. We converted the results to odds ratios using the formula  $\exp(\text{probit } \hat{\beta} \times 1.8)^{118,119}$ . We then used a Wald test to test whether the average effect of all polygenic scores for mental health problems on each ACE varies across ACEs. Lastly, we tested for statistical equivalence between different ACEs in their association with polygenic scores by (1) calculating differences in (log) odds ratios between ACEs and (2) assessing whether the 90% CIs for these differences fall within equivalence bounds of  $-0.05$  to  $0.05$ . We selected these equivalence bounds because  $0.05$  is the smallest effect size that we have 95% power to detect (log odds difference,  $0.05$ ; 95% CI,  $0.03-0.07$ ). We adopted this approach in the absence of theoretical justification for equivalence bounds<sup>115</sup>, as no previous study has tested for differences between ACEs in their association with polygenic scores for psychopathology.

We proposed to infer support for Hypothesis 1c (that parental mental illness, parental substance abuse and parental criminality would be associated with higher polygenic risk for mental health problems) if (1) the Wald test was significant ( $P < 0.05$ ) and further pairwise comparisons (between parental mental illness, parental substance abuse and parental criminality and all other ACEs) showed that these ACEs were associated with higher polygenic risk than other ACEs, and (2) the 90% CIs for these differences were not within the equivalence bounds. The interpretation of alternative patterns of results is shown in Table 1.

**Aim 2: investigate the extent to which genetic liability explains the associations between ACEs and mental health.** Hypothesis 2a. To test the proportion of the associations between ACEs and mental health (internalizing and externalizing problems) explained by observed polygenic scores, we used structural equation models in the lavaan<sup>117</sup> package. Figure 5 depicts these models, with Fig. 5a showing the underlying conceptual model, Fig. 5b showing the statistical model with one polygenic score and Fig. 5c showing the statistical model with multiple polygenic scores. As shown in Fig. 5b,c, polygenic scores were treated as mediators, because mediation and confounding are statistically equivalent<sup>121</sup>. The genetic confounding effect was therefore calculated as the indirect effect of the ACE on mental health through the polygenic scores:  $a_1b_1 + a_2b_2 + \dots + a_8b_8$ , on the basis of Fig. 5c. Notably, this estimate does not conflate genetic confounding with genetic effects on mental health mediated via exposure to ACEs (see ref. 27 and [https://osf.io/2uc4p/?view\\_only=2d9afc1b072b4507ba11ba8771aabb62](https://osf.io/2uc4p/?view_only=2d9afc1b072b4507ba11ba8771aabb62) for further explanation and simulations demonstrating this). In turn, the proportion of the association between the ACE and mental health outcome explained by the polygenic scores was calculated as  $\frac{a_1b_1 + a_2b_2 + \dots + a_8b_8}{a_1b_1 + a_2b_2 + \dots + a_8b_8 + cp}$ .

For this analysis, we included all polygenic scores (that is, eight mediators) and estimated separate models for each ACE and each mental health outcome (internalizing and externalizing problems). As a QC check, we estimated a separate model including only negative-control polygenic scores (Supplementary Fig. 2).

To obtain a single estimate reflecting the proportion of the associations between ACEs and mental health outcomes captured by observed polygenic scores, we averaged the results across six models for all ACEs (for internalizing and externalizing problems separately). This was

performed using the `agg` function from the MAd package<sup>114</sup>. Prior to aggregating the results, we planned to transform the proportions using the Freeman–Tukey double arcsine transformation<sup>122</sup> to normalize and stabilize the variance of the sampling distribution. However, it was not possible to apply this transformation across the results because several proportions were less than zero, which can arise when the direct and indirect effects are in different directions. We therefore used the raw proportions for consistency across all models. We pooled two sets of results, reflecting proportions of the associations between ACEs and mental health captured by (1) polygenic scores for mental health problems and (2) negative-control polygenic scores.

We proposed to infer support for Hypothesis 2a (that a small proportion of the associations between ACEs and mental health problems would be explained by polygenic scores) if (1) polygenic scores for mental health problems explained, on average, between 5% and 20% of the associations, and (2) the average proportion of the association explained by negative-control polygenic scores was not significantly different from zero. We proposed to interpret alternative proportions of less than 5% as ‘very small’, proportions between 20% and 40% as ‘moderate’, and proportions of more than 40% as ‘large’, broadly in line with guidance for interpreting effect sizes<sup>123</sup>.

**Hypothesis 2b.** Lastly, we estimated the proportion of the associations between ACEs and mental health problems explained by a latent polygenic score that captures SNP heritability in the mental health outcome. This genetic sensitivity analysis<sup>27,124</sup> involves estimating the structural equation model shown in Fig. 5b from a correlation matrix. This matrix includes correlations between the polygenic score and the ACE (the  $a$  path), the polygenic score and the mental health outcome (the  $b$  path), and the ACE and the mental health outcome (the  $cp$  path). Critically, this correlation matrix can be modified to reflect additional genetic variance captured in the outcome. For example, as the SNP-based heritability of parent-reported childhood internalizing problems is 6% (ref. 33), the correlation coefficient from the polygenic score to internalizing problems (the  $b$  path) can be changed to  $r = 0.24$  (calculated by taking the square root of  $0.06$ ). The correlation coefficient for the  $a$  path between the polygenic score and the ACE will also increase to  $k\sqrt{0.06}$ , where  $k$  reflects the ratio between the path from the polygenic score to the ACE and the path from the polygenic score to internalizing problems ( $k = a/b$ ). Note that the SNP heritability estimate for childhood externalizing problems that was used for this analysis is 9% (ref. 33) (hence,  $r = 0.30$ ). Supplementary Table 11 shows the method for estimating each of the original paths included in the correlation matrix.

To obtain a single estimate reflecting the proportion of the associations between ACEs and mental health outcomes captured by polygenic scores capturing SNP-based heritability, we averaged the results across six models for all ACEs (for internalizing and externalizing problems separately). As described above for Hypothesis 2a, this was performed using the MAd package<sup>125</sup>.

We proposed to infer support for Hypothesis 2b (that a moderate proportion of the association is explained by polygenic scores) if polygenic scores capturing SNP-based heritability explained between 20% and 40% of the associations between ACEs and mental health outcomes on average. We planned to interpret alternative proportions of less than 5% as ‘very small’, proportions between 5% and 20% as ‘small’, and proportions of more than 40% as ‘large’.

### Sampling plan

**Inclusion criteria and sample size.** ALSPAC. We planned to include ALSPAC children if they had data on genotype that passed QC (see the QC exclusions in Supplementary Table 8), ACEs (defined as responses to  $\geq 50\%$  of the questions in the assessments between birth and age nine years for each ACE), internalizing problems at age ten (defined as responses to  $\geq 50\%$  of items assessing separation anxiety, social anxiety,



general anxiety and major depression on the DAWBA) and externalizing problems at age ten (defined as responses to  $\geq 50\%$  of items assessing hyperkinesis/ADHD and conduct/oppositional disorders on the DAWBA). On the basis of a previous ALSPAC study using data on genotype and the DAWBA at age ten<sup>126</sup>, we expected the sample of complete cases to be about 5,900. However, to maximize the sample size and reduce selection bias due to attrition, we proposed to use multiple imputation to impute missing values in the ACEs and the internalizing and externalizing problems measures (see Supplementary Methods 2 for details of the inclusion criteria for imputation).

**ABCD.** We planned to include children from the ABCD Study if they had data on genotype that passed QC (see the QC exclusions in Supplementary Table 8), ACEs (defined as responses to  $\geq 50\%$  to items assessing each ACE), and internalizing and externalizing problems at age nine to ten (defined as responses to  $\geq 50\%$  of the relevant items on the CBCL). On the basis of previous ABCD studies using genotype data and ACEs/CBCL data, we expected the sample size to be between 4,700 and 5,400 (refs. 42,127). However, because we anticipated that the sample size may vary across different assessments (used to derive measures of ACEs and mental health), we proposed to use multiple imputation to maximize the sample size by imputing missing values in measures of ACEs and mental health (see Supplementary Methods 3 for details of the inclusion criteria for imputation).

**Power calculations.** We calculated the power to test each of our hypotheses assuming a conservative minimum sample size of  $N = 4,700$ , as the minimum expected sample sizes were 4,700 for the ABCD Study and 5,900 for ALSPAC. (Note that the ABCD Study was not originally included in the Stage 1 pre-registration, but we used it because the original dataset, CATSS, was not accessible after Stage 1 acceptance. The expected sample size for CATSS was 11,000.) We conducted each power analysis using simulation (1,000 simulated datasets) in the MASS<sup>128</sup> and stats<sup>112</sup> packages and set the  $\alpha$  level for statistical significance to 0.05. As described below, the power to test each hypothesis was  $\geq 0.95$ .

**Hypothesis 1a.** We calculated the power to obtain a single effect size reflecting the average association between polygenic scores for mental health problems and ACEs across 48 logistic regression models (that is, 8 polygenic scores  $\times$  6 ACEs). This analysis showed that the power is 0.96 to detect an average odds ratio of 1.04 for the effect of polygenic scores on ACEs using the `agg` function in the `MAd` package<sup>114</sup> (accounting for dependent effect sizes). An odds ratio of 1.04 is a conservative estimate, as the average odds ratio for the associations between polygenic scores for mental health problems and ACEs in previous research<sup>21–26</sup> was 1.10 (see [https://osf.io/2uc4p/?view\\_only=2d9afc1b072b4507ba11ba8771aaab62](https://osf.io/2uc4p/?view_only=2d9afc1b072b4507ba11ba8771aaab62) for the details).

**Hypothesis 1b.** We calculated the power to detect a significant difference in the associations between polygenic scores and ACEs according to the type of polygenic score, using a Wald test in `lavaan`<sup>117</sup>. This analysis showed that we have 1.00 power to detect a difference across eight effect sizes (reflecting the average effect of each polygenic score on ACEs) when the smallest and largest odds ratios differ by 0.11 (for example, OR = 1.05 versus 1.16), with other effect sizes taking intermediate values. A simulation using a structural equation model (shown in Supplementary Fig. 1) showed that these odds ratios are plausible assuming previously observed effects of polygenic scores on ACEs (odds ratios of between 1.03 and 1.16; ref. 21) and average correlations of  $r = 0.06$  between polygenic scores<sup>23</sup> and  $r = 0.30$  between ACEs in ALSPAC<sup>77</sup>.

**Hypothesis 1c.** Similarly to Hypothesis 1b, we calculated the power to detect a significant difference in the associations between polygenic scores and ACEs according to the type of ACE, using a Wald test in `lavaan`<sup>117</sup>. This analysis showed that we have 1.00 power to detect a

difference across six effect sizes (reflecting the average effect of all polygenic scores on each ACE) when the smallest and largest odds ratios differ by 0.10 (for example, OR = 1.05 versus 1.15), with other effect sizes taking intermediate values. As described above, these effect sizes were found to be plausible in a simulation based on the structural equation model in Supplementary Fig. 1, assuming previously observed odds ratios for the effects of polygenic scores on different ACEs varying between 1.03 and 1.16 (ref. 21) and average correlations of  $r = 0.06$  between polygenic scores<sup>23</sup> and  $r = 0.30$  between ACEs in ALSPAC<sup>77</sup>.

**Hypothesis 2a.** We calculated power for two analyses: (1) a structural equation model to estimate the proportion of the association between (individual) ACEs and mental health outcomes explained by polygenic scores, and (2) an aggregate model to average the results across individual structural equation models. For the structural equation model (shown in Fig. 5c), the power was 0.95 to detect the proportion of the association between ACEs and mental health explained by observed polygenic scores. This is assuming previously observed small, independent effects of polygenic scores for mental health problems on ACEs ( $r = 0.03–0.07$ )<sup>23</sup> and internalizing and externalizing problems ( $r = 0.01–0.05$ )<sup>84</sup>, small effects of individual ACEs on internalizing and externalizing problems ( $r = 0.06$ )<sup>129</sup>, and average correlations between polygenic scores of  $r = 0.06$  (ref. 23). For the aggregate model, the power was 1.00 to detect an average proportion of 5% (of the association between ACEs and mental health explained by polygenic scores), assuming correlations of  $r = 0.30$  between effect sizes. We consider 5% to be a conservative estimate of the likely proportion of the association between ACEs and mental health explained by multiple polygenic scores, given that prior studies have found that a single polygenic score can account for larger proportions of the associations between environmental exposures and mental health (for example, 6% (ref. 30) and 18% (ref. 28)).

**Hypothesis 2b.** We calculated power for a structural equation model with a single mediator (that is, a polygenic score capturing additional genetic variance in the outcome), as shown in Fig. 5b. The power was 1.00 to detect the proportion of the association between ACEs and mental health explained by a polygenic score that captures SNP heritability in the outcome. This is assuming a path from the polygenic score to internalizing problems of  $r = 0.24$  (that is, the square root of 0.06, as the SNP-based heritability of internalizing problems is 6% (ref. 33)), a path from the polygenic score to the ACE of  $r = 0.07$  (assuming that  $k = 0.33$ —that is, that the effect of the observed polygenic score on the ACE is a third of the size of the effect of the observed polygenic score on internalizing problems) and a path from the ACE to internalizing problems of  $r = 0.06$  (as observed previously<sup>129</sup>). Note that the power will be equally high for analyses on externalizing problems because the SNP-based heritability of externalizing problems is slightly higher than for internalizing problems (9% versus 6%; ref. 33). Furthermore, note that the power will be  $\geq 0.96$  to aggregate these results to obtain an average proportion across models, assuming that the proportion will be 5% or greater (as tested above for Hypothesis 2a). This is because as the strength of the association between polygenic scores and mental health outcomes increases, the proportion of the association between ACEs and mental health explained by polygenic scores will increase<sup>27</sup>.

### Protocol registration

The Stage 1 protocol for this Registered Report was accepted in principle on 4 January 2021. The protocol, as accepted by the journal, can be found at <https://doi.org/10.6084/m9.figshare.13580777.v1>

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

## Data availability

The ABCD Study anonymized data, including all assessment domains, are released annually to the research community. Information on how to access the ABCD data through the NDA is available on the ABCD Study data-sharing webpage: [https://abcdstudy.org/scientists\\_data\\_sharing.html](https://abcdstudy.org/scientists_data_sharing.html). Instructions on how to create an NDA study are available at <https://nda.nih.gov/training/modules/study.html>. The ABCD data repository grows and changes over time. The ALSPAC data are not publicly available, as informed consent for public data-sharing and ethical approval for public data-sharing were not obtained from the participants. Researchers can find the details of how to apply for access to the ALSPAC dataset here: <http://www.bristol.ac.uk/alspac/researchers/access/>.

## Code availability

The analysis code can be found at [https://github.com/jr-baldwin/ACEs\\_mental\\_health\\_RR](https://github.com/jr-baldwin/ACEs_mental_health_RR).

## References

- Chapman, D. P. et al. Adverse childhood experiences and the risk of depressive disorders in adulthood. *J. Affect. Disord.* **82**, 217–225 (2004).
- Hughes, K. et al. The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. *Lancet Public Health* **2**, e356–e366 (2017).
- Felitti, V. J. et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: the Adverse Childhood Experiences (ACE) Study. *Am. J. Prev. Med.* **14**, 245–258 (1998).
- Baldwin, J. R. et al. Population vs individual prediction of poor health from results of Adverse Childhood Experiences screening. *JAMA Pediatr.* **175**, 385–393 (2021).
- McLaughlin, K. A. et al. Childhood adversities and first onset of psychiatric disorders in a national sample of US adolescents. *Arch. Gen. Psychiatry* **69**, 1151–1160 (2012).
- Brown, N. M. et al. Associations between adverse childhood experiences and ADHD diagnosis and severity. *Acad. Pediatr.* **17**, 349–355 (2017).
- Hunt, T. K., Slack, K. S. & Berger, L. M. Adverse childhood experiences and behavioral problems in middle childhood. *Child Abuse Negl.* **67**, 391–402 (2017).
- Evidence-Based Early Years Intervention* (House of Commons Science and Technology Committee, 2018); <https://publications.parliament.uk/pa/cm201719/cmselect/cmsctech/>
- Adverse Childhood Experiences: What We Know, What We Don't Know, and What Should Happen Next* (Early Intervention Foundation, 2020).
- Danese, A. Annual Research Review: rethinking childhood trauma—new research directions for measurement, study design and analytical strategies. *J. Child Psychol. Psychiatry* **61**, 236–250 (2019).
- Jaffee, S. R. Child maltreatment and risk for psychopathology in childhood and adulthood. *Annu. Rev. Clin. Psychol.* **13**, 525–551 (2017).
- Polderman, T. J. et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. *Nat. Genet.* **47**, 702–709 (2015).
- Jaffee, S. R. & Price, T. S. Gene–environment correlations: a review of the evidence and implications for prevention of mental illness. *Mol. Psychiatry* **12**, 432–442 (2007).
- Plomin, R., DeFries, J. C. & Loehlin, J. C. Genotype–environment interaction and correlation in the analysis of human behavior. *Psychol. Bull.* **84**, 309–322 (1977).
- Sidebotham, P., Golding, J. & Team, A. S. Child maltreatment in the “Children of the Nineties”: a longitudinal study of parental risk factors. *Child Abuse Negl.* **25**, 1177–1200 (2001).
- O'Connor, T. G., Deater-Deckard, K., Fulker, D., Rutter, M. & Plomin, R. Genotype–environment correlations in late childhood and early adolescence: antisocial behavioral problems and coercive parenting. *Dev. Psychol.* **34**, 970 (1998).
- Marceau, K. et al. Gene–environment correlation underlying the association between parental negativity and adolescent externalizing problems. *Child Dev.* **84**, 2031–2046 (2013).
- Baldwin, J. R. et al. Adolescent victimization and self-injurious thoughts and behaviors: a genetically sensitive cohort study. *J. Am. Acad. Child Adolesc. Psychiatry* **58**, 506–513 (2019).
- Baldwin, J. R., Ayorech, Z., Rijdsdijk, F. V., Schoeler, T. & Pingault, J.-B. Cyber-victimisation and mental health in young people: a co-twin control study. *Psychol. Med.* **51**, 2620–2630 (2021).
- Van IJzendoorn, M. H., Euser, E. M., Prinzie, P., Juffer, F. & Bakermans-Kranenburg, M. J. Elevated risk of child maltreatment in families with stepparents but not with adoptive parents. *Child Maltreat.* **14**, 369–375 (2009).
- Sallis, H. M. et al. Genetic liability to schizophrenia is associated with exposure to traumatic events in childhood. *Psychol. Med.* **51**, 1814–1821 (2020).
- Zwicker, A. et al. Neurodevelopmental and genetic determinants of exposure to adversity among youth at risk for mental illness. *J. Child Psychol. Psychiatry* **61**, 536–544 (2019).
- Schoeler, T. et al. Multi–polygenic score approach to identifying individual vulnerabilities associated with the risk of exposure to bullying. *JAMA Psychiatry* **76**, 730–738 (2019).
- Coleman, J. R. et al. Genome-wide gene–environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK Biobank. *Mol. Psychiatry* **25**, 1–17 (2020).
- Peyrot, W. J. et al. Does childhood trauma moderate polygenic risk for depression? A meta-analysis of 5765 subjects from the Psychiatric Genomics Consortium. *Biol. Psychiatry* **84**, 138–147 (2018).
- Warrier, V. & Baron-Cohen, S. Childhood trauma, life-time self-harm, and suicidal behaviour and ideation are associated with polygenic scores for autism. *Mol. Psychiatry* **26**, 1670–1684 (2019).
- Pingault, J.-B. et al. Genetic sensitivity analysis: adjusting for genetic confounding in epidemiological associations. *PLoS Genet.* **17**, e1009590 (2021).
- Lehto, K. et al. Childhood adoption and mental health in adulthood: the role of gene–environment correlations and interactions in the UK Biobank. *Biol. Psychiatry* **87**, 708–716 (2020).
- Wertz, J. et al. Using DNA from mothers and children to study parental investment in children's educational attainment. *Child Dev.* **91**, 1745–1761 (2019).
- Krapohl, E. et al. Widespread covariation of early environmental exposures and trait-associated polygenic variation. *Proc. Natl Acad. Sci. USA* **114**, 11727–11732 (2017).
- Holmlund, H., Lindahl, M. & Plug, E. The causal effect of parents' schooling on children's schooling: a comparison of estimation methods. *J. Econ. Lit.* **49**, 615–651 (2011).
- Krapohl, E. & Plomin, R. Genetic link between family socioeconomic status and children's educational achievement estimated from genome-wide SNPs. *Mol. Psychiatry* **21**, 437–443 (2016).
- Cheesman, R. et al. Childhood behaviour problems show the greatest gap between DNA-based and twin heritability. *Transl. Psychiatry* **7**, 1284 (2017).
- Cheesman, R. et al. Extracting stability increases the SNP heritability of emotional problems in young people. *Transl. Psychiatry* **8**, 223 (2018).
- Mullins, N. et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nat. Genet.* **53**, 817–829 (2021).

36. Stahl, E. A. et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nat. Genet.* **51**, 793–803 (2019).
37. Ratanatharathorn, A. et al. Polygenic risk for autism, attention-deficit hyperactivity disorder, schizophrenia, major depressive disorder, and neuroticism is associated with the experience of childhood abuse. *Mol. Psychiatry* **26**, 1696–1705 (2021).
38. Peel, A. J. et al. Genetic and early environmental predictors of adulthood self-reports of trauma. *Br. J. Psychiatry* <https://doi.org/10.1192/bjp.2021.207> (2022).
39. Walsh, D., McCartney, G., Smith, M. & Armour, G. Relationship between childhood socioeconomic position and adverse childhood experiences (ACEs): a systematic review. *J. Epidemiol. Community Health* **73**, 1087–1093 (2019).
40. Olds, D. L. et al. Long-term effects of home visitation on maternal life course and child abuse and neglect: fifteen-year follow-up of a randomized trial. *JAMA* **278**, 637–643 (1997).
41. Feinberg, M. E. et al. Couple-focused prevention at the transition to parenthood, a randomized trial: effects on coparenting, parenting, family violence, and parent and child adjustment. *Prev. Sci.* **17**, 751–764 (2016).
42. Warrier, V. et al. Gene–environment correlations and causal effects of childhood maltreatment on physical and mental health: a genetically informed approach. *Lancet Psychiatry* **8**, 373–386 (2021).
43. Lecei, A. et al. Evidence that the association of childhood trauma with psychosis and related psychopathology is not explained by gene–environment correlation: a monozygotic twin differences approach. *Schizophr. Res.* **205**, 58–62 (2019).
44. Baldwin, J. R. et al. Childhood maltreatment and mental health problems: a systematic review and meta-analysis of quasi-experimental studies. *Am. J. Psychiatry* (in the press).
45. Eley, T. C. et al. The intergenerational transmission of anxiety: a children-of-twins study. *Am. J. Psychiatry* **172**, 630–637 (2015).
46. Silberg, J. L., Maes, H. & Eaves, L. J. Genetic and environmental influences on the transmission of parental depression to children’s depression and conduct disturbance: an extended Children of Twins study. *J. Child Psychol. Psychiatry* **51**, 734–744 (2010).
47. McAdams, T. et al. The relationship between parental depressive symptoms and offspring psychopathology: evidence from a children-of-twins study and an adoption study. *Psychol. Med.* **45**, 2583–2594 (2015).
48. Haber, J. R., Jacob, T. & Heath, A. C. Paternal alcoholism and offspring conduct disorder: evidence for the ‘common genes’ hypothesis. *Twin Res. Hum. Genet.* **8**, 120–131 (2005).
49. Waldron, M., Martin, N. G. & Heath, A. C. Parental alcoholism and offspring behavior problems: findings in Australian children of twins. *Twin Res. Hum. Genet.* **12**, 433–440 (2009).
50. Kendler, K., Ohlsson, H., Sundquist, K. & Sundquist, J. Cross-generational transmission from drug abuse in parents to attention-deficit/hyperactivity disorder in children. *Psychol. Med.* **46**, 1301–1309 (2016).
51. Bornovalova, M. A. et al. Understanding the relative contributions of direct environmental effects and passive genotype–environment correlations in the association between familial risk factors and child disruptive behavior disorders. *Psychol. Med.* **44**, 831–844 (2014).
52. D’Onofrio, B. M. et al. A children of twins study of parental divorce and offspring psychopathology. *J. Child Psychol. Psychiatry* **48**, 667–675 (2007).
53. D’Onofrio, B. M. et al. A genetically informed study of marital instability and its association with offspring psychopathology. *J. Abnorm. Psychol.* **114**, 570 (2005).
54. Baldwin, J. R. & Degli Esposti, M. Triangulating evidence on the role of perceived versus objective experiences of childhood adversity in psychopathology. *JCPP Adv.* **1**, e12010 (2021).
55. Pingault, J. B. et al. Research Review: how to interpret associations between polygenic scores, environmental risks, and phenotypes. *J. Child Psychol. Psychiatry* <https://doi.org/10.1111/jcpp.13607> (2022).
56. Duncan, L. et al. Analysis of polygenic risk score usage and performance in diverse human populations. *Nat. Commun.* **10**, 1–9 (2019).
57. Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat. Genet.* **51**, 584–591 (2019).
58. Gage, S. H., Davey Smith, G., Ware, J. J., Flint, J. & Munafò, M. R. G=E: what GWAS can tell us about the environment. *PLoS Genet.* **12**, e1005765 (2016).
59. Dunn, E. C. et al. Research review: gene–environment interaction research in youth depression—a systematic review with recommendations for future research. *J. Child Psychol. Psychiatry* **52**, 1223–1238 (2011).
60. Schoeler, T., Duncan, L., Cecil, C. M., Ploubidis, G. B. & Pingault, J.-B. Quasi-experimental evidence on short- and long-term consequences of bullying victimization: a meta-analysis. *Psychol. Bull.* **144**, 1229 (2018).
61. Ahmadzadeh, Y. I. et al. Systematic review and meta-analysis of genetically informed research: associations between parent anxiety and offspring internalizing problems. *J. Am. Acad. Child Adolesc. Psychiatry* **60**, 823–840 (2021).
62. Baldwin, J. R., Pingault, J.-B., Schoeler, T., Sallis, H. M. & Munafò, M. R. Protecting against researcher bias in secondary data analysis: challenges and potential solutions. *Eur. J. Epidemiol.* **37**, 1–10 (2022).
63. Franco, A., Malhotra, N. & Simonovits, G. Publication bias in the social sciences: unlocking the file drawer. *Science* **345**, 1502–1505 (2014).
64. Holmes, M. V. et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. *Br. Med. J.* **349**, g4164 (2014).
65. Fergusson, D. M., Boden, J. M. & Horwood, L. J. Tests of causal links between alcohol abuse or dependence and major depression. *Arch. Gen. Psychiatry* **66**, 260–266 (2009).
66. Kendler, K. S., Ohlsson, H., Sundquist, K. & Sundquist, J. Drug abuse-associated mortality across the lifespan: a population-based longitudinal cohort and co-relative analysis. *Soc. Psychiatry Psychiatr. Epidemiol.* **52**, 877–886 (2017).
67. Murray, J., Blokland, A., Farrington, D. P. & Theobald, D. Long-term effects of conviction and incarceration on men in the Cambridge Study in Delinquent Development. in *Labeling Theory* (eds Murray, J. & Farrington, D. P.) 209–235 (Routledge, 2017).
68. *Trauma-Focused Cognitive Behavioural Therapy* (Early Intervention Foundation, 2020); <https://guidebook.eif.org.uk/programme/trauma-focused-cognitive-behavioural-therapy#about-the-programme>
69. Auchter, A. M. et al. A description of the ABCD organizational structure and communication framework. *Dev. Cogn. Neurosci.* **32**, 8–15 (2018).
70. Clark, D. B. et al. Biomedical ethics and clinical oversight in multisite observational neuroimaging studies with children and adolescents: the ABCD experience. *Dev. Cogn. Neurosci.* **32**, 143–154 (2018).
71. Boyd, A. et al. Cohort profile: the ‘children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children. *Int. J. Epidemiol.* **42**, 111–127 (2013).
72. Fraser, A. et al. Cohort profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. *Int. J. Epidemiol.* **42**, 97–110 (2012).



73. Northstone, K. et al. The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample of index children in 2019. *Wellcome Open Res.* **4** (2019).
74. Dong, M. et al. The interrelatedness of multiple forms of childhood abuse, neglect, and household dysfunction. *Child Abuse Negl.* **28**, 771–784 (2004).
75. *Adverse Childhood Experiences International Questionnaire (ACE-IQ)* (World Health Organization, 2018).
76. Houtepen, L., Heron, J., Suderman, M., Tilling, K. & Howe, L. Adverse childhood experiences in the children of the Avon Longitudinal Study of Parents and Children (ALSPAC). *Wellcome Open Res.* **3** (2018).
77. Russell, A. E. et al. Pathways between early-life adversity and adolescent self-harm: the mediating role of inflammation in the Avon Longitudinal Study of Parents and Children. *J. Child Psychol. Psychiatry* **60**, 1094–1103 (2019).
78. Goodman, R., Ford, T., Richards, H., Gatward, R. & Meltzer, H. The Development and Well-Being Assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology. *J. Child Psychol. Psychiatry* **41**, 645–655 (2000).
79. Aebi, M. et al. The use of the Development and Well-Being Assessment (DAWBA) in clinical practice: a randomized trial. *Eur. Child Adolesc. Psychiatry* **21**, 559–567 (2012).
80. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
81. Anderson, C. A. et al. Data quality control in genetic case-control association studies. *Nat. Protoc.* **5**, 1564 (2010).
82. Marees, A. T. et al. A tutorial on conducting genome-wide association studies: quality control and statistical analysis. *Int. J. Methods Psychiatr. Res.* **27**, e1608 (2018).
83. *GWAS Data Generation: Details as of 26/11/2012* (University of Bristol, 2012); <http://www.bristol.ac.uk/media-library/sites/alspac/migrated/documents/gwas-data-generation.pdf?u07022013>
84. Akingbuwa, W. A. et al. Genetic associations between childhood psychopathology and adult depression and associated traits in 42998 individuals: a meta-analysis. *JAMA Psychiatry* **77**, 715–728 (2020).
85. Taylor, M. J. et al. Association of genetic risk factors for psychiatric disorders and traits of these disorders in a Swedish population twin sample. *JAMA Psychiatry* **76**, 280–289 (2019).
86. Kandaswamy, R., Allegrini, A. G., Cave, S. N., Plomin, R. & von Stumm, S. Predicting alcohol use from genome-wide polygenic scores, environmental factors, and their interactions in young adulthood. *Psychosom. Med.* **84**, 244–250 (2022).
87. Tielbeek, J. J. et al. Genome-wide association studies of a broad spectrum of antisocial behavior. *JAMA Psychiatry* **74**, 1242–1250 (2017).
88. Tielbeek, J. J. et al. Uncovering the genetic architecture of broad antisocial behavior through a genome-wide association study meta-analysis. *Molecular Psychiatry* <https://doi.org/10.1038/s41380-022-01793-3> (2022).
89. Choi, S. W., Mak, T. S. H., Hoggart, C. J. & O'Reilly, P. F. EraSOR: erase sample overlap in polygenic score analyses. Preprint at *bioRxiv* <https://doi.org/10.1101/2021.12.10.472164> (2021).
90. Euesden, J., Lewis, C. M. & O'Reilly, P. F. PRSice: polygenic risk score software. *Bioinformatics* **31**, 1466–1468 (2014).
91. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk score analyses. *Nat. Protoc.* **15**, 2759–2772 (2020).
92. Heeringa, S. G. & Berglund, P. A. A guide for population-based analysis of the Adolescent Brain Cognitive Development (ABCD) Study baseline data. Preprint at *bioRxiv* <https://doi.org/10.1101/2020.02.10.942011> (2020).
93. Garavan, H. et al. Recruiting the ABCD sample: design considerations and procedures. *Dev. Cogn. Neurosci.* **32**, 16–22 (2018).
94. Michelini, G. et al. Delineating and validating higher-order dimensions of psychopathology in the Adolescent Brain Cognitive Development (ABCD) study. *Transl. Psychiatry* **9**, 1–15 (2019).
95. Hoffman, E. A. et al. Stress exposures, neurodevelopment and health measures in the ABCD study. *Neurobiol. Stress* **10**, 100157 (2019).
96. Geller, B. et al. Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) mania and rapid cycling sections. *J. Am. Acad. Child Adolesc. Psychiatry* **40**, 450–455 (2001).
97. Kaufman, J. et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. *J. Am. Acad. Child Adolesc. Psychiatry* <https://doi.org/10.1097/00004583-199707000-00021> (1997).
98. Schaefer, E. S. Children's reports of parental behavior: an inventory. *Child Dev.* **36**, 413–424 (1965).
99. Moos, R. H. *Family Environment Scale Manual: Development, Applications, Research* (Consulting Psychologists Press, 1994).
100. Moos, R. H. Conceptual and empirical approaches to developing family-based assessment procedures: resolving the case of the Family Environment Scale. *Fam. Process* **29**, 199–208 (1990).
101. Rice, J. P. et al. Comparison of direct interview and family history diagnoses of alcohol dependence. *Alcohol. Clin. Exp. Res.* **19**, 1018–1023 (1995).
102. Achenbach, T. M. *Manual for the Young Adult Self-Report and Young Adult Behavior Checklist* (Univ. of Vermont, Department of Psychiatry, 1997).
103. Rescorla, L. A. & Achenbach, T. M. The Achenbach System of Empirically Based Assessment (ASEBA) for ages 18 to 90 years. in *The Use of Psychological Testing for Treatment Planning and Outcomes Assessment: Instruments for Adults* (ed Maruish, M. E.) 115–152 (Lawrence Erlbaum Associates, 2004).
104. Tiet, Q. Q. et al. Relationship between specific adverse life events and psychiatric disorders. *J. Abnorm. Child Psychol.* **29**, 153–164 (2001).
105. Achenbach, T. *Manual for the Child Behaviour Checklist and 1991 Profile* (Department of Psychiatry, Univ. of Vermont, 1991).
106. Achenbach, T. & Rescorla, L. *Manual for the ASEBA School-Age Forms & Profiles* 99–135 (ASEBA, 2001).
107. Achenbach, T. M. in *Encyclopedia of Clinical Neuropsychology* (eds Kreutzer, J. S. et al.) 546–552 (Springer, 2011).
108. Baurley, J. W., Edlund, C. K., Pardamean, C. I., Conti, D. V. & Bergen, A. W. Smokescreen: a targeted genotyping array for addiction research. *BMC Genomics* **17**, 1–12 (2016).
109. Lam, M. et al. RICOPILI: Rapid Imputation for COnsortias PIpeLine. *Bioinformatics* **36**, 930–933 (2020).
110. Ohi, K. et al. Polygenic risk scores for major psychiatric and neurodevelopmental disorders contribute to sleep disturbance in childhood: Adolescent Brain Cognitive Development (ABCD) Study. *Transl. Psychiatry* **11**, 1–11 (2021).
111. Hatoum, A. S. et al. Polygenic risk scores for alcohol involvement relate to brain structure in substance-naïve children: results from the ABCD Study. *Genes Brain Behav.* **20**, e12756 (2021).
112. R Core Team. R: A Language and Environment for Statistical Computing v.3.6.2 (R Foundation for Statistical Computing, 2019).
113. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. B* **57**, 289–300 (1995).
114. Del Re, A. A practical tutorial on conducting meta-analysis in R. *Quant. Methods Psychol.* **11**, 37–50 (2015).



115. Lakens, D. Equivalence tests: a practical primer for *t* tests, correlations, and meta-analyses. *Soc. Psychol. Pers. Sci.* **8**, 355–362 (2017).
116. Lakens, D., Scheel, A. M. & Isager, P. M. Equivalence testing for psychological research: a tutorial. *Adv. Methods Pract. Psychol. Sci.* **1**, 259–269 (2018).
117. Rosseel, Y. Lavaan: an R package for structural equation modeling and more. Version 0.5–12 (BETA). *J. Stat. Softw.* **48**, 1–36 (2012).
118. Muthén, L. K. & Muthén, B. *Regression Analysis, Exploratory Factor Analysis, Confirmatory Factor Analysis, and Structural Equation Modeling for Categorical, Censored, and Count Outcomes* (Mplus, 2009); <http://statmodel.com/download/Topic%202-v20%20%5BCompatibility%20Mode%5D1.pdf>
119. Agresti, A. *An Introduction to Categorical Data Analysis* (John Wiley & Sons, 2018).
120. *Test for a Difference in Two Odds Ratios* (Genome Toolbox, 2014); <http://genometoolbox.blogspot.com/2014/06/test-for-difference-in-two-odds-ratios.html>
121. MacKinnon, D. P., Krull, J. L. & Lockwood, C. M. Equivalence of the mediation, confounding and suppression effect. *Prev. Sci.* **1**, 173–181 (2000).
122. Freeman, M. F. & Tukey, J. W. Transformations related to the angular and the square root. *Ann. Math. Stat.* **21**, 607–611 (1950).
123. Funder, D. C. & Ozer, D. J. Evaluating effect size in psychological research: sense and nonsense. *Adv. Methods Pract. Psychol. Sci.* **2**, 156–168 (2019).
124. Pingault, J.-B. et al. Using genetic data to strengthen causal inference in observational research. *Nat. Rev. Genet.* **19**, 566 (2018).
125. Del Re, A. & Hoyt, W. T. MA: Meta-analysis with mean differences. R package, version 0.8-2.1 (2014).
126. Nivard, M. G. et al. Genetic overlap between schizophrenia and developmental psychopathology: longitudinal and multivariate polygenic risk prediction of common psychiatric traits during development. *Schizophr. Bull.* **43**, 1197–1207 (2017).
127. Waszczuk, M. A. et al. General v. specific vulnerabilities: polygenic risk scores and higher-order psychopathology dimensions in the Adolescent Brain Cognitive Development (ABCD) Study. *Psychol. Med.* 1–10 (2021).
128. Venables, W. N. & Ripley, B. D. *Modern Applied Statistics with S-PLUS* (Springer Science & Business Media, 2013).
129. Cecil, C. A., Viding, E., Fearon, P., Glaser, D. & McCrory, E. J. Disentangling the mental health impact of childhood abuse and neglect. *Child Abuse Negl.* **63**, 106–119 (2017).
- U01DA041048, U01DA050989, U01DA051016, U01DA041022, U01DA051018, U01DA051037, U01DA050987, U01DA041174, U01DA041106, U01DA041117, U01DA041028, U01DA041134, U01DA050988, U01DA051039, U01DA041156, U01DA041025, U01DA041120, U01DA051038, U01DA041148, U01DA041093, U01DA041089, U24DA041123 and U24DA041147. A full list of supporters is available at <https://abcdstudy.org/federal-partners.html>. A listing of the participating sites and a complete listing of the study investigators can be found at [https://abcdstudy.org/consortium\\_members/](https://abcdstudy.org/consortium_members/). ABCD consortium investigators designed and implemented the study and/or provided data but did not necessarily participate in the analysis or writing of this report. This manuscript reflects the views of the authors and may not reflect the opinions or views of the National Institutes of Health or ABCD consortium investigators. We thank G. Sudre for his support with the QC of the ABCD genetic data. This research was funded in whole or in part by the Wellcome Trust (grant no. 215917/Z/19/Z). For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. L.D.H. is supported by a Career Development Award fellowship from the UK Medical Research Council (no. MR/M020894/1). H.M.S., A.S.F.K., M.M. and L.D.H. work in a unit that receives funding from the University of Bristol and the UK Medical Research Council (grant nos MC\_UU\_00011/5 and MC\_UU\_00011/7). H.M.S. and M.M. are supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the University Hospitals Bristol National Health Service Foundation Trust and the University of Bristol. M.M. and H.M.S. are members of the UK Centre for Tobacco and Alcohol Studies, a UKCRC Public Health Research: Centre of Excellence. A.D. was funded by the Medical Research Council (grant no. P005918) and by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no role in study design, data analysis, decision to publish or preparation of the manuscript.

## Author contributions

Author contributions are presented according to the CRediT (Contributor Roles Taxonomy). J.R.B.: Conceptualization, methodology, formal analysis, data curation, writing—original draft, writing—review and editing, project administration, funding acquisition. H.M.S.: Software, data curation, writing—review and editing. T.S.: Software, data curation, writing—review and editing. M.J.T.: Software, data curation, writing—review and editing. A.S.F.K.: Writing—review and editing. J.J.T.: Software, resources, writing—review and editing. W.B.: Software, resources, data curation, writing—review and editing. V.W.: Software, writing—review and editing. L.D.H.: Software, data curation, writing—review and editing. A.D.: Conceptualization, writing—review and editing. E.M.: Writing—review and editing. F.R.: Methodology. H.L.: Investigation, writing—review and editing. S.L.: Investigation, writing—review and editing. R.K.: Software, data curation. P.L.: Conceptualization, investigation, writing—review and editing. M.M.: Conceptualization, writing—review and editing, supervision. J.-B.P.: Conceptualization, methodology, formal analysis, data curation, writing—original draft, writing—review and editing, supervision.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41562-022-01482-9>.

## Acknowledgements

We thank all the ALSPAC families who took part in the study, the midwives for their help in recruiting them and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and Wellcome (grant no. 102215/2/13/2) and the University of Bristol provide core support for ALSPAC data collection. A comprehensive list of grant funding is available on the ALSPAC website. The GWAS data were generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. Other data used in the preparation of this Article were obtained from the ABCD Study (<https://abcdstudy.org>), held in the NIMH Data Archive (NDA). This is a multisite, longitudinal study designed to recruit more than 10,000 children aged nine to ten and follow them over ten years into early adulthood. The ABCD Study is supported by the National Institutes of Health and additional federal partners under award numbers

**Correspondence and requests for materials** should be addressed to Jessie R. Baldwin.

**Peer review information** *Nature Human Behaviour* thanks Rachel Latham, Ana Goncalves-Soares and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

© The Author(s), under exclusive licence to Springer Nature Limited 2022

<sup>1</sup>Department of Clinical, Educational and Health Psychology, Division of Psychology and Language Sciences, University College London, London, UK. <sup>2</sup>Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. <sup>3</sup>MRC Integrative Epidemiology Unit at the University of Bristol, Bristol Medical School, University of Bristol, Bristol, UK. <sup>4</sup>School of Psychological Science, University of Bristol, Bristol, UK. <sup>5</sup>NIHR Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK. <sup>6</sup>Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. <sup>7</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. <sup>8</sup>Division of Psychiatry, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK. <sup>9</sup>CNCR, Amsterdam Neuroscience Campus, VU University, Amsterdam, the Netherlands. <sup>10</sup>Department of Psychiatry, University of Cambridge, Cambridge, UK. <sup>11</sup>Department of Child & Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. <sup>12</sup>National and Specialist CAMHS Trauma, Anxiety, and Depression Clinic, South London and Maudsley NHS Foundation Trust, London, UK. <sup>13</sup>Anna Freud National Centre for Children and Families, London, UK. <sup>14</sup>Psychology Department, Faculty of Social Sciences, Anton de Kom University, Paramaribo, Suriname. <sup>15</sup>School of Medical Sciences, Örebro University, Örebro, Sweden. <sup>16</sup>Gillberg Neuropsychiatry Centre, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden. <sup>17</sup>Centre for Ethics, Law and Mental Health (CELAM), Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden. ✉e-mail: [j.baldwin@ucl.ac.uk](mailto:j.baldwin@ucl.ac.uk)

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a                                 | Confirmed  |
|-------------------------------------|--|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of all covariates tested   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated   |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The ABCD Study anonymized data, including all assessment domains, are released annually to the research community. Information on how to access ABCD data through the NDA is available on the ABCD Study data-sharing webpage: [https://abcdstudy.org/scientists\\_data\\_sharing.html](https://abcdstudy.org/scientists_data_sharing.html). Instructions on how to create an NDA study are available at <https://nda.nih.gov/training/modules/study.html>. The ABCD data repository grows and changes over time.

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

### Reporting on sex and gender

We controlled for sex but did not present sex-specific results because there was not a strong theoretical reason to expect sex differences in gene-environment correlations or genetic confounding. This is because previous studies on gene-environment correlations involving childhood adversity have not detected sex differences (Schoeler et al., 2019), and studies on ACEs and mental health have not found sex differences (McLaughlin et al., 2012; Mersky et al., 2013; Lee and Chen, 2017; Houtepen et al., 2020).

### Population characteristics

See above

### Recruitment

ALSPAC: ALSPAC sought to recruit all pregnant women in the former county of Avon, United Kingdom, with an expected due date between April 1, 1991 and December 31, 1992. The initial ALSPAC sample consists of 14,541 pregnancies. This is the number of pregnancies for which the mother enrolled in the ALSPAC study and had either returned at least one questionnaire or attended a "Children in Focus" clinic by 19/07/99.

ABCD Study: Children aged 9-10 years were recruited through probability sampling of public and private elementary schools within the catchment areas of the 21 research sites. School selection was based on gender, race and ethnicity, socioeconomic status, and urbanicity. Inclusion criteria were the child's age and attending a public or private elementary school within the catchment areas. Exclusion criteria for children were limited to not being fluent in English, having a parent not fluent in English or Spanish, major medical or neurological conditions, gestational age <28 weeks or birthweight <1200g, contraindications to MRI scanning, a history of traumatic brain injury, a current diagnosis of moderate/severe autism spectrum disorder, intellectual disability, schizophrenia, or alcohol/substance use disorder.

### Ethics oversight

ALSPAC: Ethics approval for ALSPAC was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. Consent for biological samples has been collected in accordance with the Human Tissue Act (2004).

ABCD Study: Ethics approval for the ABCD Study was given by a central Institutional Review Board (IRB) at the University of California, San Diego, and in some cases by individual site IRBs (e.g. Washington University in St. Louis). Parents or guardians provided written informed consent after the procedures had been fully explained and children assented before participation in the study.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

### Study description

Prospective longitudinal birth cohort study (ALSPAC) and prospective longitudinal cohort study (ABCD Study)

### Research sample

We chose to use data from the Avon Longitudinal Study of Parents and Children (ALSPAC) and the Adolescent Brain and Cognitive Development (ABCD) Study, as both are large longitudinal cohort studies with genotype data, prospective measures of ACEs, and child mental health data. In ALSPAC, 49% of the analytic sample was female and in the ABCD Study, 47% was female. Analysis was limited to individuals of European descent to match the ancestry of the GWAS discovery samples. Therefore, the samples are not fully representative of the communities the participants reside in.

### Sampling strategy

ALSPAC aimed to recruit all women resident in a defined geographical area in the South West of England with an expected date of delivery between 1 April 1991 and 31 December 1992 (85% participation). The ABCD Study aimed to utilize a multi-stage probability sample of eligible youth, selecting a stratified, probability sample of schools across the U.S. in order to capture demographic diversity.

### Data collection

ALSPAC and ABCD are existing cohort studies and the researchers involved in this study were not involved in data collection. The study staff who collected ALSPAC and ABCD data were thus blind to this manuscript's hypothesis (which was developed several years after data were collected).



ALSPAC: Children have been followed-up and assessed repeatedly across development through questionnaires, face-to-face interviews and physical and psychological assessments (including biological assays). ACEs were assessed using parent questionnaires (and very occasionally, child questionnaires) and mental health was assessed using parent questionnaires. ALSPAC children have been genotyped using the Illumina HumanHap550 quad chip genotyping platforms by 23andme subcontracting the Wellcome Trust Sanger Institute, Cambridge, UK and the Laboratory Corporation of America, Burlington, NC, US.

ABCD: Assessments were made through in-person visits. Like ALSPAC, ACEs were assessed using parent questionnaires (and very occasionally, child questionnaires) and mental health was assessed using parent questionnaires. Children from the ABCD Study have been genotyped from blood and saliva samples using the Affymetrix NIDA SmokeScreen Array.

Timing	ALSPAC includes children born between between April 1, 1991 and December 31, 1992, assessed repeatedly (~40 times) between birth (1991-1992) up to age 10 years (2001-2002). ABCD includes children born during the period 2006-2008, assessed at age 9-10 (2017-2018) and age 10-11 (2018-2019).
Data exclusions	Exclusion criteria were pre-established and included participants who (1) did not pass genotyping quality control, (2) had less than 10% data on ACEs, and (3) did not have data on mental health.
Non-participation	Complete cases included N=4,106 in ALSPAC and N=4,662 in the ABCD Study. We used multiple imputation to impute missing data for participants with 10% data on ACEs and some available data on mental health (imputed sample sizes were 6,411 for ALSPAC and 4,996 for the ABCD Study).
Randomization	Participants were not randomised to ACEs because of obvious ethical concerns. Analyses controlled for sex and where relevant, polygenic scores for psychiatric disorders.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging